Disrupting interaction of sound hedgehoge-SURF4 to treat cancer
Patent Information
- Application Number
- CN202380021439.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-14
- Filing Date
- 2023-02-10
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2043-02-10
AI Technical Summary
然而,这些抑制剂在配体依赖性癌症类型中没有显示出功效
[0013] In certain embodiments, the CW motif in Shh is necessary and sufficient for ER-to-Golgi transport of ShhN. Excess site protein 4 (SURF4) interacts directly with the CW motif of ShhN to regulate the packaging of ShhN into COPII vesicles. ShhN interacts with SURF4 at the ER and dissociates from each other after entering the Golgi apparatus. The CW motif is known to interact with proteoglycans (PG), which are mainly synthesized in the Golgi apparatus. PG competes with SURF4 for binding to ShhN, and inhibition of PG synthesis results in defects in ShhN export from the trans-Golgi network (TGN). SURF4 and PG maturation are also important for intracellular trafficking of full-length Shh in mammalian cells.
Smart Images

Figure HDA0004988997160000011 
Figure HDA0004988997160000021 
Figure HDA0004988997160000022
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. filed on February 14, 2022.
[0003] 63 / 309,648, the entire contents of which (including any tables, figures or drawings) are incorporated herein by reference. Background Art
[0004] The Hedgehog (Hh) signaling pathway plays an important role in various developmental processes in metazoans (1, 2). Mutations in key components regulating Hh signaling are associated with many human diseases (3). Hh was first discovered in the cuticle of Drosophila larvae.
[0005] It mediates larval segment development and adult appendage morphology (4). In mammals, there are three Hh family members: Sonic hedgehog (Shh), Indian hedgehog (Ihh), and Desert hedgehog (Dhh). Ihh regulates chondrocyte proliferation and differentiation (5).
[0006] Dhh acts in the gonads, where it regulates testicular organogenesis, spermatogenesis (6, 7), and follicle development in the ovary (8). The functions of Shh are more extensive than those of the other two Hh members: it regulates embryonic morphology (4), specification of cell types in the nervous system (9), axon guidance (10), cell differentiation, and organ development (11).
[0007] Hh is synthesized as a full-length precursor Hh (HhFL). After entering the ER, HhFL is automatically cleaved into two parts: the N-terminal Hedge domain (HhN) and the C-terminal Hog domain (HhC) (1). HhC is degraded by ER-associated degradation (12). HhN is lipid-modified, in which a cholesterol molecule is covalently attached to the C-terminus and a palmitoyl group is attached to the N-terminus (13-15). The lipid-modified HhN then exits the ER and is delivered to the plasma membrane via the secretory pathway. Once at the plasma membrane, Hh is released into the extracellular matrix (ECM) and is ultimately recognized by Hh receptors on the plasma membrane of target cells to induce downstream signaling.
[0008] Although significant progress has been made in understanding the Hh signaling pathway in target cells, the molecular mechanisms that mediate the secretion of newly synthesized Shh proteins from producer cells remain unclear. The ER is the first stop for newly synthesized proteins to enter the secretory pathway. In this compartment, cargo proteins are typically recognized by the coat protein complex II (COPII) and packaged into vesicles and exported from the ER. Soluble cargo proteins in the ER lumen cannot bind directly to the COPII coat but are instead captured into vesicles by transmembrane cargo receptors. One mammalian cargo receptor, ERGIC53, is a mannose-specific lectin that recognizes N-linked glycoproteins in the ER lumen (16, 17). The p24 family of proteins function as cargo receptors to regulate the ER export of glycosylphosphatidylinositol (GPI)-anchored proteins (18). The mammalian homolog of yeast, the ER vesicle (Erv) protein, is also thought to function as a cargo receptor (16). Surfeit locus protein 4 (SURF4), the mammalian ortholog of Erv29p, regulates the ER export of soluble proteins, including lipoproteins and proprotein convertase subtilisin / kexin type 9 (PCSK9) (19-21). SURF4 recognizes the amino-terminal tripeptide motif of soluble cargo proteins and participates in the organization of ER export sites (ERES) (19, 22). The cargo receptor that mediates the sorting of Shh in the secretory pathway remains unknown.
[0009] Abnormal activation of the Hh signaling pathway has been shown to accelerate cancer development. All existing Hh pathway inhibitors approved by the FDA or in clinical trials target downstream components of Hh ligand reception, such as SMO and Gli. However, these inhibitors have not shown efficacy in ligand-dependent cancer types.
[0010] Therefore, there remains a need to target Shh signaling to inhibit cancer development, especially for ligand-dependent cancer types. Summary of the invention
[0011] The present invention relates to compositions and methods for blocking the interaction between sonic hedgehog (Shh) and excess locus protein 4 (SURF4), particularly for treating subjects having or at risk of developing cancer. The methods of the present invention block the interaction between SURF4 and Shh by mutating residues E50, D53, D56, or any combination thereof, of SURF4, or by mutating the Cardin-Weintraub (CW) motif (amino acid residues 32-38) of human Shh. Amino acid residues 32-38 in human Shh correspond to amino acid residues 33-39 in mouse Shh. The present invention also relates to a composition comprising: a polypeptide containing the CW motif at positions 32-38 of human Shh, a polypeptide containing the first lumenal loop (residues 49-60) of human SURF4, a chemical small molecule that blocks the interaction between SURF4 and Shh, or any combination thereof, and a method of administering a composition to a subject in need thereof, the composition comprising: a polypeptide containing the CW motif at positions 32-38 of human Shh, a polypeptide containing the first lumenal loop (residues 49-60) of human SURF4, a chemical small molecule that blocks the interaction between SURF4 and Shh, or any combination thereof.
[0012] In certain embodiments, the small chemical molecule is a glycosaminoglycan, such as, for example, heparin or heparan sulfate.
[0013] In certain embodiments, the CW motif in Shh is necessary and sufficient for ER-to-Golgi transport of ShhN. Surplus site protein 4 (SURF4) directly interacts with the CW motif of ShhN to regulate the packaging of ShhN into COPII vesicles. ShhN interacts with SURF4 at the ER and dissociates from each other after entering the Golgi. The CW motif is known to interact with proteoglycans (PGs) synthesized primarily in the Golgi. PGs compete with SURF4 for binding to ShhN, and inhibition of PG synthesis results in defects in the export of ShhN from the trans-Golgi network (TGN). SURF4 and PG maturation are also important for the intracellular trafficking of full-length Shh in mammalian cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] This patent or patent application file contains at least one drawing drawn in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0015] Figures 1A to 1N ER-to-Golgi trafficking of ShhN depends on its KRRHPKK (SEQ ID NO: 6) motif. Figure 1A and Figure 1D . Using the gene encoding Str-KDEL and SBP-EGFP-ShhN25-198 ( Figure 1A Picture AB, Figure 1D Figure KM) or SBP-EGFP-tagged fragments or mutant forms of ShhN ( Figure 1A Picture CH, Figure 1D Figure NP) plasmids were used to transfect HeLa cells. On day 1 post-transfection, after incubation with biotin for the indicated times, the localization of RUSH constructs containing different forms of ShhN was analyzed. Scale bar, 10 μm. Magnification, 63x. Figure 1B and Figure 1E Quantification of the percentage of cells showing juxtanuclear accumulated EGFP signal after incubation with biotin for the indicated times (mean ± SD; n = 3; > 100 cells were counted at each time point). **, p < 0.01. Figure 1C .Interspecies sequence alignment of amino acids 33-49 of mouse Shh. Figure 1F HEK293T cells were transfected with plasmids encoding the indicated constructs. On day 1 post-transfection, cells were incubated with biotin for 2 h. After biotin incubation, culture media and cell lysates were analyzed by immunoblotting for wild-type (wt) or mutant forms of SBP-EGFP-ShhN using anti-HA and anti-SEC22B antibodies. 25-198 -HA levels. Figure 1G . Relative to the level detected in the wt group, secreted SBP-EGFP-ShhN 25-198 Quantification results normalized to the level of -HA (mean ± SD; n = 3). In each experimental group, the abundance of ShhN secretion after biotin treatment was normalized to the abundance of ShhN in cell lysates before biotin treatment. **, p < 0.01. Figure 1H . Schematic diagram depicting the vesicle formation assay for release of reconstituted ShhN-HA into transport vesicles. Figures 1I to 1K as well as Figure 1N . Use as in the case of ShhN encoding wt or mutant forms 1-198 Cells transfected with the plasmids expressing ERGIC53-HA were subjected to vesicle formation using the indicated reagents. Vesicle fractions were analyzed by immunoblotting using anti-HA or anti-ERGIC53 antibodies. Figure 1L to Figure 1M .ShhN-HA packaged into transport vesicles ( Figure 1L ) or ERGIC53( Figure 1M ) (mean ± SD; n = 3). ***, p < 0.001; NS, no significant difference.
[0016] Figures 2A to 2K SURF4 mediates the packaging of ShhN into transport vesicles and regulates ER-to-Golgi trafficking and secretion of ShhN. Figure 2A HeLa cells were transfected with negative control (NC) siRNA or two different siRNAs targeting SURF4. 24 hours after transfection, the cells were incubated with a vector encoding SBP-EGFP-ShhN 25-198 Cells were re-transfected with plasmids containing Str-KDEL. On day 3 after knockdown, cells were incubated with biotin for the indicated times, and the localization of the indicated proteins was analyzed using antibodies against endogenous TGN46 and SURF4. Scale bar, 10 μm. Magnification, 63x. Figure 2C to Figure 2D The levels of SURF4 and ERGIC53 in cell lysates from HeLa cells transfected with NC siRNA or with siRNA against SURF4 were analyzed by immunoblotting using anti-SURF4 and anti-ERGIC53 antibodies ( Figure 2C ) and from HEK293Trex WT or SURF4 KO cells ( Figure 2D ). Figure 2E .Using the gene encoding SBP-EGFP-ShhN 25-198 Wild-type or SURF4 KO HEK293Trex cells were transfected with plasmids containing ShhN and Str-KDEL. On day 3 after knockdown, cells were incubated with biotin for the indicated times and analyzed for the localization of ShhN. Scale bar, 10 μm. Magnification, 63x. Figure 2B and Figure 2F .SBP-EGFP-ShhN showing juxtanuclear localization 25-198 Quantification of the percentage of cells expressing β-actin (mean ± SD; n = 3; > 100 cells were counted in each experiment). **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Figure 2G .Use the specified amount of ShhN encoding HA tag 1-198 Wild-type or SURF4KO cells were transfected with plasmids containing ShhN-HA. On day 1 after transfection, ShhN-HA levels in the culture medium and cell lysates were analyzed by immunoprecipitation and immunoblotting using anti-HA antibodies. FIG. 2H to FIG. 2I In wild-type cells ( Figure 2H ) and SURF4 KO cells ( Fig.2I ), vesicle formation was performed using the indicated reagents. Vesicle fractions were analyzed by immunoblotting using anti-ERGIC53 or anti-HA antibodies. Figure 2J to Figure 2K .ShhN-HA packaged into transport vesicles ( Figure 2J ) or ERGIC53( Figure 2K ) (n=3; mean±SD). **, p<0.01; NS, no significant difference.
[0017] FIG. 3A to FIG. 3O The CW motif of ShhN directly interacts with the predicted first lumenal loop of SURF4. Figure 3A .Purified GST or GST-tagged human ShhN 25-49 Incubated with lysates of HEK293T cells transfected with SURF4-HA. After incubation, bound proteins were analyzed by immunoblotting using anti-HA antibody. Figure 3B . Binding to GST or ShhN 25-49 The relative levels of SURF4-HA bound to GST or ShhN were quantified (n=3; mean ± SD). 25-49 The levels of SURF4-HA bound to -GST were normalized to the corresponding bait protein, and then in each experimental group, the values were normalized to the levels of SURF4-HA bound to GST. ****, p<0.0001. Figure 3C HEK293T cells were co-transfected with plasmids encoding the indicated constructs. On day 1 post-transfection, cells were treated in 2 mM DSP and cell lysates were incubated with beads conjugated with HA antibodies. Bound proteins were analyzed by immunoblotting using anti-HA or anti-Myc antibodies. Figure 3D . Relative to SURF4 binding to ShhN-HA, -HA was normalized to the percentage of SURF4. The normalized abundance was then quantified (n=3; mean±SD). ***, p<0.001. Figure 3E .The structure of SURF4 predicted by AlphaFold. Hydrophobic amino acids are highlighted in light blue. Figure 3F Co-IP was performed in HEK293T cells expressing the indicated constructs in the presence of DSP. Bound proteins were analyzed by immunoblotting using anti-HA or anti-Myc antibodies. Figure 3G . SURF4 bound to ShhN-HA WT -Percentage of Myc normalized to SURF4 ED-AA -Percentage of Myc. The normalized abundance was then quantified (n=3; mean±SD). *, p<0.05. Figure 3H and Figure 3J .Purification of GST and Shh from E. coli 25-49 -GST, GST-SURF4 49-60 and analyzed by Coomassie Brilliant Blue staining. Fig. 3I and Figure 3KCW or SURF4-cavity peptides were covalently linked to thiopyridone agarose 6B and incubated with the indicated prey proteins. After incubation, bound proteins were analyzed by immunoblotting using anti-GST antibodies. Figure 3L to Figure 3M .Isothermal titration calorimetry (ITC) was used to determine the interaction between CW peptide and GST-SURF4 49-60 or the interaction between GST. Figure 3N CW, CW(KR-AA), or RRFR peptides were covalently linked to thiopyridone agarose 6B and GST-SURF4 49-60 After incubation, bound proteins were analyzed by immunoblotting using anti-GST antibody. Fig.3O . For GST-SURF4 bound to the indicated peptides 49-60 The levels of GST-SURF4 bound to CW peptide were quantified (n=3; mean ± SD). 49-60 The quantitative results were normalized to the level of . **, p < 0.01; ****, p < 0.0001.
[0018] FIG. 4A to FIG. 4E .Proteoglycan synthesis regulates ShhN export from the TGN. Figure 4A .HeLa cells were treated with (or not treated with) 2.5 mM xyloside. 24 hours after xyloside treatment, the expression of Str-KDEL and SBP-EGFP-ShhN 25-198 The cells were transfected with the plasmid. 48 hours after xyloside treatment, the cells were treated with biotin and incubated at 20°C for 2 hours. The cells were then incubated at 32°C for 0 min ( Figure 4A Picture AF) or 45min( Figure 4A Figure GL). SBP-EGFP-ShhN 25-198 The localization of 100 μg / mL and TGN46 was analyzed. Scale bar, 10 μm. Magnification, 63x. Magnified views of the indicated areas in images A, D, G, and J are shown in images A', D', G', and J'. Figure 4B . Each expressing cell was stained with SBP-EGFP-ShhN 25-198 The number of labeled punctate structures was quantified (n=3; mean±SD, more than 25 cells were quantified in each experimental group). ****, p<0.0001. Figure 4C HeLa cells were transfected with NC siRNA or two different siRNAs targeting XYLT2. 48 hours after transfection, the cells were inoculated with siRNAs encoding Str-KDEL and SBP-EGFP-ShhN 25-198The cells were re-transfected with plasmids containing Shh. On day 3 after knockdown, cells were treated with biotin and incubated at 20°C for 2 hours. Cells were then incubated at 32°C for 0 or 45 min and analyzed for Shh localization. Scale bar, 10 μm. Magnification, 63x. Magnified views of the designated areas in images QS are shown in images Q'-S'. Figure 4D HEK293T cells were transfected with negative control (NC) siRNA or siRNA against XYLT2. 48 hours after transfection, cells were re-transfected with a plasmid encoding Myc-XYLT2. On day 3 after knockdown, the levels of SEC22B and Myc-XYLT2 in cell lysates were analyzed by immunoblotting using anti-Myc or anti-SEC22B antibodies. Figure 4E At different time points after biotin treatment, each cell contained SBP-EGFP-ShhN 25-198 Quantitative results of the number of punctate structures (n=3, mean±SD, more than 20 cells were quantified in each experimental group). **, p<0.01.
[0019] FIG. 5A to FIG. 5H .PG competes with SURF4 for binding to ShhN and promotes the transport of ShhN through the Golgi apparatus. Figure 5A Purified GST-tagged human ShhN 25-49 Incubated with lysates of HEK293T cells transfected with SURF4-HA. After incubation, bound proteins were analyzed by immunoblotting using anti-HA antibody. Figure 5B . Binding to ShhN 25-49- The relative levels of SURF4-HA bound to GST were quantified (n=3; mean ± SD). The quantitative results in each experimental group were compared with those bound to ShhN in the absence of heparin. 25-49 -GST levels of SURF4-HA were normalized. *, p < 0.05. FIG. 5C to FIG. 5D HEK293T cells were transfected with negative control (NC) siRNA or siRNA targeting XYLT2. 48 hours after transfection, the cells were inoculated with siRNA encoding SURF4-Myc and SBP-EGFP-ShhN 25-198 -HA (called SBP-EGFP-ShhN-HA) plasmid was re-transfected into cells. On day 3 after knockdown, cells were incubated at 20°C for 2 hours in the absence or presence of biotin. Cells were then treated with 2mM DSP, and cell lysates were incubated with beads conjugated with HA antibodies. Bound proteins were analyzed by immunoblotting using anti-HA or anti-Myc antibodies. Figure 5E. The relative level of SURF4-Myc bound to SBP-EGFP-ShhN-HA was quantified (n=3; mean±SD). In each experimental group, the level of SURF4-Myc bound after biotin treatment was normalized to the level of SURF4-Myc bound before biotin treatment. *, p<0.05. Fig. 5F The model of the present invention describes the molecular mechanisms regulating the sorting and secretion of ShhN. Figure 5G HeLa cells transfected with negative control siRNA (NC) or siRNA against XYLT2 (XYLT2 KD) were treated with biotin for 20 min or 30 min and analyzed for the localization of the indicated proteins. Scale bar, 10 μm. Magnification, 63x. Magnified views of the indicated areas in images L, P, S, V, Y are shown in images L', P', S', V', Y'. Figure 5H . Quantification of colocalization of SBP-EGFP-ShhN and GM130 in the juxtanuclear region marked by SBP-EGFP-ShhN. ****, p<0.0001.
[0020] FIG. 6A to FIG. 6D .Proteoglycan synthesis regulates SBP-EGFP-Shh FL Delivery of the TGN to the cell surface. Fig. 6A .Unprocessed( Fig. 6A Figures AF) or treated with 2.5 mM xyloside ( Fig. 6A Figure GI) HeLa cells. 24 hours after xylosidase treatment, cells were transfected with the gene encoding Str-KDEL_SBP-EGFP-HA-Shh FL 48 hours after xyloside treatment, cells were not treated with biotin ( Fig. 6A Figures AC) or treated with biotin for 1 hour ( Fig. 6A Image DI). Mouse anti-HA antibody was then used for antibody uptake assay. Surface and total SBP-EGFP-HA-Shh were detected by immunofluorescence FL . Scale bar, 10 μm. Magnification, 63x. Figure 6B . Quantification results showing the percentage of cells with surface localized Shh (mean ± SD; n = 3; > 50 cells were counted in each group). ***, p < 0.001. Figure 6C HeLa cells were transfected with NC siRNA or two different siRNAs targeting XYLT2. 48 hours after transfection, the cells were inoculated with siRNAs encoding Str-KDEL and SBP-EGFP-Shh FLCells were re-transfected with plasmids containing Shh. On day 3 after knockdown, cells were treated with biotin and incubated at 20°C for 2 h. Cells were then incubated at 32°C for 0 or 45 min and analyzed for the localization of Shh constructs. Scale bar, 10 μm. Magnification, 63x. Magnified views of the designated areas in panel NP are shown in panels N'-P'. Fig.6D At different time points after biotin treatment, each cell contained SBP-EGFP-Shh FL Quantitative results of the number of punctate structures (n=3, mean±SD, more than 20 cells were quantified in each experimental group). **, p<0.01; ***, p<0.001.
[0021] 7A to 7F Residues 33–49 in ShhN are important for ER export of ShhN. Fig. 7A .Shows a schematic diagram of the RUSH test. Figure 7B .Using the gene encoding SBP-EGFP-ShhN 25-198 HeLa cells were transfected with plasmids containing 100 μM dT and streptavidin-KDEL. On day 1 after transfection, cells were left untreated or treated with biotin for 15 min. The localization of the indicated proteins was then analyzed by immunofluorescence. Scale bar, 10 μm. Magnification, 63x. Figure 7C . shows the quantitative results of co-localization of ShhN and TGN46 in all cells showing the juxtanuclear localization form of SBP-EGFP-ShhN after 15 min of biotin treatment (n=3). Fig.7D . Using the gene encoding Str-KDEL and SBP-EGFP-ShhN 25-198 ( Fig.7D Image KM) or SBP-EGFP ( Fig.7D Image NP) or different truncated forms of ShhN tagged with SBP-EGFP ( Fig.7D Figures Q-AE) were used to transfect HeLa cells with plasmids. The localization of RUSH constructs containing different forms of ShhN was analyzed after incubation with biotin for the indicated times, day 1 after transfection. Scale bar, 10 μm. Magnification, 63x. Fig. 7E Quantification of the percentage of cells showing juxtanuclear accumulated EGFP signal 30 min after biotin treatment (mean ± SD; n = 3; >100 cells were counted at each time point). Figure 7F . Schematic diagram depicting the ShhN fragment that can be transported to the Golgi apparatus.
[0022] FIG. 8A to FIG. 8D SURF4 was identified as a binding partner of ShhN. FIG. 8A to FIG. 8B HEK293T cells were either kept untransfected or transfected with proteins encoding ShhN1-198 -HA (ShhN-HA) or IGF2-HA plasmid transfection. On the first day after transfection, the cells were lysed, ShhN-HA or IGF2-HA was immunoprecipitated, and the results were analyzed by SDS-PAGE and Coomassie Brilliant Blue staining ( Fig. 8A ) or immunoblotting using anti-HA antibody ( Figure 8B ) were analyzed. Asterisks indicate the location of IGF2-HA or ShhN-HA. Figure 8C Label-free quantification was performed to quantify the intensity of unique peptides to determine the abundance of proteins identified by mass spectrometry. The table shows a list of the following proteins in the elution fractions: The abundance of the proteins in the ShhN-HA group was calculated to be greater than 3 times the abundance detected in the IGF2-HA group. Fig.8D HEK293T cells were transfected with plasmids encoding the indicated constructs. On day 1 post-transfection, cells were treated with 2 mM DSP and cell lysates were incubated with beads conjugated with anti-HA antibodies. The indicated binding proteins were analyzed by immunoblotting using anti-HA or anti-Myc antibodies.
[0023] FIG. 9A to FIG. 9B .Expression of siRNA-resistant SURF4 rescued the defect in ER-to-Golgi trafficking of ShhN in SURF4 knockdown cells. Fig.9A Figure AR. Negative control (NC) siRNA ( Fig.9A Figures AB, GH, and MN) or siRNA against SURF4 ( Fig.9A Figures CF, IL and OR) were transfected into HeLa cells. 48 hours after transfection, the cells were transfected with the gene encoding Str-KDEL_SBP-EGFP-ShhN 25-198 ( Fig.9A Figures AD, GJ and MP), or encoding siRNA-resistant SURF4 RS -HA and Str-KDEL_SBP-EGFP-ShhN 25-198 ( Fig.9A Figures EF, KL, and QR) were re-transfected with plasmids of ShhN. On day 3 after knockdown, cells were incubated with biotin for the indicated times and analyzed for ShhN localization. Scale bar, 10 μm. Magnification, 63x. Fig. 9B .SBP-EGFP-ShhN showing juxtanuclear localization 25-198 Quantitative results of the percentage of cells with β-cells (n=4, mean±SD, the number of cells quantified in each experimental group was more than 100). **, p<0.01; ns, no significant difference.
[0024] FIG. 10A to FIG. 10B SURF4 regulates SBP-EGFP-ShhN33-39 ER to Golgi transport. Fig. 10A . Use negative control (NC) siRNA ( Fig. 10A Figures A, D) or two different siRNAs targeting SURF4 ( Fig. 10A Figures B, E, C, and F) HeLa cells were transfected with SBP-EGFP-ShhN 33-39 Cells were re-transfected with plasmids containing Str-KDEL and Str-KDEL. On day 3 after knockdown, cells were incubated with biotin for the indicated times and analyzed for the localization of the indicated proteins. Scale bar, 10 μm. Magnification, 63x. Fig. 10B .SBP-EGFP-ShhN showing juxtanuclear localization 33-39 Quantification of the percentage of cells expressing SHH (mean ± SD; n = 3; > 100 cells were counted in each experiment). **, p < 0.01. Note: Shh used in this figure is from mouse.
[0025] FIG. 11A to FIG. 11C .Knockdown of SURF4 does not cause defects in ER-to-Golgi transport and IGF2 secretion. Fig.11A Figure AF. Negative control (NC) siRNA ( Fig.11A Figures A to C) or siRNA targeting SURF4 ( Fig.11A Figures DF) HeLa cells were transfected. 48 hours after transfection, cells were re-transfected with a plasmid encoding Str-KDEL_SBP-EGFP-IGF2. On day 3 after knockdown, cells were incubated with biotin for the indicated times and analyzed for the localization of IGF2. Scale bar, 10 μm. Magnification, 63x. Fig. 11B . Quantification results showing the percentage of cells expressing juxtanuclear localized SBP-EGFP-IGF2 (n=3, mean±SD, more than 100 cells were quantified in each experimental group). Fig. 11C HEK293T cells were transfected with control siRNA or siRNA against SURF4. 24 hours after transfection, cells were re-transfected with plasmids encoding Str-KDEL and SBP-EGFP-IGF2-HA. On day 3 after knockdown, cells were incubated with biotin for 2 hours. After biotin incubation, the levels of SBP-EGFP-IGF2-HA in the culture medium and cell lysates were analyzed by immunoblotting using anti-HA or anti-SEC22B antibodies.
[0026] Fig.12 . The co-localization between SBP-EGFP-ShhN and SURF4 or SEC31A was analyzed using permeabilized cell assay. 25-198HeLa cells were transfected with 547p3 / 4e3p3 (referred to as SBP-EGFP-ShhN). On day 1 after transfection, cells were either untreated (panels AC) or treated with biotin for 4 min (panels DO). Subsequently, cells were permeabilized with digitonin and incubated with the indicated reagents. After incubation, the localization of the indicated proteins was analyzed by immunofluorescence. Scale bar, 10 μm. Magnified views of the indicated areas in panels F and I are shown in panels F'-F"' and I'-I"'. Magnified views of the indicated areas in panel O are shown in panels O'-P"'.
[0027] FIG. 13A to FIG. 13H SURF4 is transported from the ER to the Golgi apparatus together with ShhN. Fig.13A Image A. SBP-EGFP-ShhN 25-198 (SBP-EGFP-ShhN) and SURF4-HA were co-transfected into HeLa cells. On the first day after transfection, 0 min after biotin treatment ( Fig.13A Picture AC), 20min( Fig.13A Image DF) or 60min( Fig.13A Panel GI) Analysis of localization of the indicated proteins. Fig. 13B . Quantification results of the percentage of cells showing Golgi-localized SURF4-HA in cells co-expressing SURF4-HA and SBP-EGFP-ShhN at 0 min or 20 min after biotin treatment (n=3, mean±SD, more than 100 cells were quantified in each experimental group). **, p<0.01. Fig. 13C Figure KM. Analysis of the localization of ERGIC53 and GM130 in HeLa cells. Fig.13D . Quantitative results of colocalization between GM130 and ERGIC53 (n=3, mean±SD, more than 20 cells were quantified in each experimental group). Fig.13E Panel OV. HeLa cells co-transfected with SURF4-HA and SBP-EGFP-ShhN were treated with biotin for 20 min and analyzed for the localization of the indicated proteins. Scale bar, 10 μm. Magnification, 63x. Fig.13F . Quantitative results of colocalization between SURF4-HA and ERGIC53 or GM130 (n=3, mean±SD, more than 20 cells were quantified in each experimental group). ****, p<0.0001. Figure 13GHEK293T cells were co-transfected with plasmids encoding SURF4-Myc and SBP-EGFP-ShhN-HA. On day 1 post-transfection, cells were incubated at 20°C for 2 h in the presence or absence of biotin. Cells were then treated in 2 mM DSP, and cell lysates were incubated with beads conjugated with HA antibodies. Bound proteins were analyzed by immunoblotting using anti-HA or anti-Myc antibodies. Fig.13H . The relative level of SURF4-Myc binding to SBP-EGFP-ShhN-HA was quantified (n=3, mean±SD). *, p<0.05.
[0028] FIG. 14A to FIG. 14B Xyloside treatment did not cause a defect in ER-to-Golgi translocation of ShhN. Fig.14A Panels AD. HeLa cells were untreated or treated with 2.5 mM xyloside. 24 hours after xyloside treatment, cells were transfected with proteins encoding Str-KDEL and SBP-EGFP-ShhN 25-198 Cells were transfected with plasmids containing (SBP-EGFP-ShhN). 48 hours after xyloside treatment, cells were incubated with biotin for the indicated times. After biotin incubation, localization of SBP-EGFP-ShhN was analyzed. Scale bar, 10 μm. Magnification, 63x. Fig. 14B . Quantification results showing the percentage of cells with juxtanuclear localization of SBP-EGFP-ShhN (n=3, mean±SD, more than 100 cells were quantified in each experimental group). ns, no significant difference.
[0029] FIG. 15A to FIG. 15C .Real-time imaging analysis of SBP-EGFP-ShhN surface delivery. Fig.15A Image AP”. HeLa cells were left untreated or treated with 2.5 mM xyloside. 24 hours after xyloside treatment, cells were transfected with proteins encoding Str-KDEL and SBP-EGFP-ShhN 25-198 Cells were transfected with plasmids containing (SBP-EGFP-ShhN). A series of time-lapse confocal images of SBP-EGFP-ShhN after biotin addition were acquired at 30-second intervals 48 hours after xyloside post-treatment. Representative images at selected time points are shown. Magnified views of the designated areas in panels CD, GH, KL, and OP are shown in panels C'-D", G'-H", K'-L", O'-P". Scale bar, 10 μm. Magnification, 63x. Fig. 15B Quantification of the number of SBP-EGFP-ShhN punctate structures per cell at different time points after biotin treatment. Fig. 15CQuantification of the number of punctate structures containing SBP-EGFP-ShhN per cell 50 min after biotin treatment (mean ± SD, each dot represents one cell). **, p < 0.01.
[0030] FIG. 16A to FIG. 16D Lowering the pH to 6.0 did not promote the release of SURF4 from ShhN. Fig.16A .Purified ShhN 25-49 -GST was incubated with lysates from HEK293T cells transfected with SURF4-HA at pH 6.0 or pH 7.2. After incubation, bound proteins were analyzed by immunoblotting using anti-HA antibody. Fig. 16B . Binding to ShhN 25-49 The relative levels of SURF4-HA bound to ShhN at pH 7.2 were quantified (n=3, mean ± SD). 25-49 The levels of SURF4-HA bound to -GST were normalized to the corresponding bait protein and then, within each experimental group, this value was expressed relative to that bound to ShhN at pH 6.0. 25-49 The levels of SURF4-HA were normalized to those of -GST. ns. No significant differences. Fig. 16C Purified ShhN was incubated in the presence of heparin at a specified concentration at pH 6.0. 25-49 -GST was incubated with lysates of HEK293T cells transfected with SURF4-HA. After incubation, bound proteins were analyzed by immunoblotting using anti-HA antibody. Fig.16D . Binding to ShhN 25 -49 The relative levels of SURF4-HA bound to ShhN-GST were quantified (n=3, mean±SD). In each experimental group, the quantitative results were compared to the level of SURF4-HA bound to ShhN in the absence of heparin. 25-49 -GST levels of SURF4-HA were normalized. *, p < 0.05.
[0031] 17A to 17D .SBP-EGFP-Shh FL Processed into N-terminal and C-terminal fragments. Fig.17A . Western blotting was performed to analyze the cells expressing SBP-EGFP-HA-Shh using anti-HA antibody FL (HA-Shh FL ) or SBP-EGFP-Shh FL -HA(Shh FL HA-tagged Shh in cell lysates of HEK293T cells FL . Fig. 17B . The gene encoding Str-KDEL and SBP-EGFP-HA-Shh FL HEK293T cells transfected with plasmids were incubated in the presence or absence of biotin for 2 h. After incubation, Shh levels in the culture medium and cell lysates were analyzed by immunoblotting using anti-HA antibody. Fig. 17C . Using the gene encoding Str-KDEL and SBP-EGFP-Shh FL -HA plasmid transfected HeLa cells. On the first day after transfection, 0 min after biotin treatment ( Fig. 17C Image CE) or 20min( Fig. 17C Panels FH) Analysis of the localization of the indicated proteins. Scale bar, 10 μm. Magnification, 63x. Fig.17D . Quantification results of the percentage of cells showing juxtanuclear localization of SBP-EGFP-ShhN and ShhC-HA at 0 min or 20 min after biotin treatment (n=3, mean±SD, more than 100 cells were quantified in each experimental group). ****, p<0.0001.
[0032] 18A to 18D SURF4 regulates SBP-EGFP-Shh FL ER to Golgi transport. Fig.18A Figure AR. Negative control (NC) siRNA ( Fig.18A Figures AF) or siRNA against SURF4 ( Fig.18A Figure GR) HeLa cells were transfected with Str-KDEL_SBP-EGFP-Shh FL ( Fig.18A Figures AL), or encoding siRNA-resistant SURF4 RS -HA and Str-KDEL_SBP-EGFP-Shh FL ( Fig.18A Figure MR) plasmid was re-transfected into cells. On day 3 after knockdown, cells were incubated with biotin for the indicated times and analyzed for Shh localization. Fig.18B . Use the gene encoding Str-KDEL_SBP-EGFP-Shh FL Plasmid transfection ( Fig.18B SX), or with siRNA encoding resistance to SURF4 RS -HA and Str-KDEL_SBP-EGFP-Shh FL Retransfection with plasmid ( Fig.18BPanels Y-AA) Wild-type (wt) or SURF4 KO HEKTrex cells. On day 3 after knockdown, cells were incubated with biotin for 15 min and analyzed for the localization of the indicated proteins. Scale bar, 10 μm. Magnification, 63x. FIG. 18C to FIG. 18D .SBP-EGFP-Shh showing juxtanuclear localization FL Quantitative results of the percentage of cells with β-cells (n=3, mean±SD, the number of cells quantified in each experimental group was more than 100). **, p<0.01; ***, p<0.001.
[0033] FIG. 19A to FIG. 19B Blocking proteoglycan synthesis does not inhibit surface delivery of SBP-EGFP-E-cadherin. Fig.19A Image AL. Unprocessed ( Fig.19A Figures AF) or treated with 2.5 mM xyloside ( Fig.19A Figure GL) HeLa cells. 24 hours after xyloside treatment, cells were transfected with a plasmid encoding SBP-EGFP-E-cadherin. On day 3 after xyloside treatment, cells were treated with biotin and incubated at 20°C for 2 hours. Cells were then incubated at 32°C for 0 min ( Fig.19A Image AC, GI) or 45min( Fig.19A Panels DF, JL). Analysis of localization of the indicated constructs. Scale bar, 10 μm. Fig.19B . Quantification results showing the percentage of cells with surface localized SBP-EGFP-E-cadherin (n=3, mean±SD, more than 100 cells were quantified in each experimental group). ns No significant difference.
[0034] Fig. 20 . Schematic diagram of the present invention.
[0035] Brief description of sequence
[0036] SEQ ID NO: 1: SURF4 sgRNA
[0037] SEQ ID NO: 2: siRNA against SURF4
[0038] SEQ ID NO: 3: siRNA against SURF4
[0039] SEQ ID NO:4: siRNA against XYLT2
[0040] SEQ ID NO:5: siRNA against XYLT2
[0041] SEQ ID NO:6: Cardin-Weintraub peptide
[0042] SEQ ID NO:7: Cardin-Weintraub peptide
[0043] SEQ ID NO:8: Cardin-Weintraub peptide
[0044] SEQ ID NO:9: Cardin-Weintraub peptide MT Peptides
[0045] SEQ ID NO: 10: SURF4 peptide
[0046] SEQ ID NO:11: RRFR peptide
[0047] SEQ ID NO: 12: SURF4 peptide
[0048] SEQ ID NO: 13: Nucleotide sequence encoding the Cardin-Weintraub peptide of SEQ ID NO: 8
[0049] SEQ ID NO: 14: Nucleotide sequence encoding the SURF4 peptide of SEQ ID NO: 10
[0050] SEQ ID NO: 15: Human SURF4 amino acid sequence
[0051] SEQ ID NO: 16: Human SURF4 cDNA nucleotide sequence
[0052] SEQ ID NO: 17: Human sonic hedgehog amino acid sequence
[0053] SEQ ID NO: 18: Human sonic hedgehog cDNA nucleotide sequence DETAILED DESCRIPTION
[0054] Selected Definition
[0055] As used herein, the singular forms "a," "an," "the," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. In addition, when the terms "include," "comprise," "contain," "have," "have," "with," or variations thereof are used in the detailed description and / or claims, such terms are intended to be inclusive in a manner similar to the term "comprising." The transitional words / phrases (and any grammatical variations thereof) "comprise," "include," "contain," include the phrases "consist essentially of," "consist essentially of," "consist of," and "consist of."
[0056] The phrase "consisting essentially of" or "composed essentially of" means that the claimed aspect covers embodiments including the specified materials or steps as well as those that do not materially affect the basic and novel characteristics of the claimed aspect.
[0057] The term "about" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. Where specific values are described in the application and claims, the term "about" should be considered to mean within an acceptable error range for the specific value unless otherwise indicated.
[0058] In the present disclosure, scope is stated in shorthand form to avoid having to list and describe each value in the scope in detail. Depending on the circumstances, any suitable value in the range can be selected as the upper limit, lower limit or end value of the range. For example, a range of 1 to 10 represents end values 1 and 10, and intermediate values 2, 3, 4, 5, 6, 7, 8, 9, and all intermediate ranges included in 1 to 10, such as 2 to 5, 2 to 8, and 7 to 10. In addition, when using scope in this article, it is intended to clearly include combinations and sub-combinations of scopes (e.g., sub-ranges within the disclosed range) and specific embodiments thereof.
[0059] As used herein, the term "nucleic acid" or "polynucleotide" refers to a polymer of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and single-stranded or double-stranded forms thereof. Unless otherwise specified, the term encompasses those nucleic acids comprising known analogs of natural nucleotides, which have binding properties similar to the nucleic acids mentioned and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise specified, a particular nucleic acid sequence also implies that conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, homologous sequences, single nucleotide polymorphisms (SNPs) and complementary sequences as well as sequences explicitly indicated are encompassed. Specifically, degenerate codon substitution can be achieved by generating the following sequence: wherein, the third position of one or more selected (or all) codons is substituted with mixed base and / or deoxyinosine residues (see Batzer et al., Nucleic Acid Res. 19: 5081 (1991); Ohtsuka et al., J. Biol. Chem. 260: 2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8: 91-98 (1994)). The term nucleic acid can be used interchangeably with gene, cDNA and mRNA encoded by a gene.
[0060] As used herein, an "isolated" or "purified" nucleic acid molecule, polynucleotide, polypeptide, protein or organic compound such as a macromolecule (e.g., those described below) is substantially free of other compounds with which it is associated in nature, such as cellular material. A purified or isolated polynucleotide (ribonucleic acid (RNA) or deoxyribonucleic acid (DNA)) is free of the genes or sequences that flank it in its naturally occurring state. A purified or isolated polypeptide is free of the amino acids or sequences that flank it in its naturally occurring state. An isolated microbial strain refers to a strain that has been removed from the environment in which it occurs in nature. Thus, an isolated strain may exist, for example, as a biologically pure culture or as spores (or other forms of strains) associated with a carrier.
[0061] As used herein, the term "macromolecule" refers to a biological substance including, for example, a protein, a peptide, an antibody, or a blood component.
[0062] As used herein, the term "gene" refers to a DNA segment involved in producing a polypeptide chain; it includes regions before and after the coding region (leader and trailer regions) that participate in the transcription / translation of the gene product and regulate transcription / translation, as well as intervening sequences (introns) between individual coding segments (exons).
[0063] In this application, the terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids. The terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of the corresponding naturally occurring amino acids, as well as naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. As used herein, the terms encompass amino acid chains of any length, including full-length proteins, in which the amino acid residues are linked by covalent peptide bonds.
[0064] As used herein, "vector" refers to a DNA molecule, such as a plasmid, used to introduce a nucleotide construct (e.g., a DNA construct) into a host cell. Cloning vectors typically contain one or a small amount of restriction endonuclease recognition sites and marker genes suitable for identifying and selecting cells transformed with the cloning vector, wherein the restriction endonuclease recognition sites can be inserted into exogenous DNA sequences in a determinable manner without losing the basic biological function of the vector. Marker genes typically include genes that provide selective characteristics such as tetracycline resistance, hygromycin resistance, or ampicillin resistance.
[0065] As used herein, in the case of describing two or more polynucleotide sequences, the term "identical" or "percent (%) identity" refers to two or more sequences or subsequences of identical nucleotides that are identical or have a specified percentage on the comparison region. For example, when using a comparison algorithm or by manual comparison and visual inspection to measure and compare and compare on a comparison window or on a specified region to obtain maximum correspondence, the homologous nucleotide sequence used in the method of the present invention has at least 80% sequence identity with the reference sequence, preferably 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity. For polynucleotide sequences, this definition also refers to the complementary sequence of the test sequence.
[0066] Endogenous nucleic acid is a nucleic acid that naturally exists in a cell. For example, a nucleic acid that exists in the genomic DNA of a cell is an endogenous nucleic acid.
[0067] Exogenous nucleic acid is any nucleic acid that does not naturally occur in a cell. For example, a nucleic acid vector introduced into a cell constitutes an exogenous nucleic acid. Other examples of exogenous nucleic acids include vectors comprising a heterologous promoter linked to an endogenous nucleic acid (e.g., a nucleic acid encoding a kinase).
[0068] The present invention provides for the use of "homologous amino acid sequences" or "homologues of amino acid sequences". Homologues of amino acid sequences are understood to mean any amino acid sequence obtained by mutation (particularly mutation of the encoding nucleotide sequence) according to techniques well known to those skilled in the art and showing changes relative to the parent sequence. For example, mutations in the regulatory and / or promoter sequences used to express the polypeptide that result in altered expression levels of the polypeptide according to the invention provide "homologues of amino acid sequences". Similarly, substitutions, deletions or additions of nucleic acids in the polynucleotides of the present invention provide "homologues" of the encoded amino acid sequences. In various embodiments, "homologues" of amino acid sequences have substantially the same biological activity as the corresponding reference amino acid sequence, i.e., proteins homologous to natural proteins have the same biological activity as naturally occurring proteins. Typically, a homologue of an amino acid sequence has at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence. These percentages are merely statistically significant, and the differences between two amino acid sequences can be randomly distributed and can be distributed over the entire sequence length.
[0069] The present invention provides for the use of "homologous nucleic acid sequences" or "homologs of nucleic acid sequences". Homologs of nucleic acid sequences are understood to mean any nucleotide sequence obtained by mutation according to techniques well known to those skilled in the art and showing changes relative to the parent sequence. For example, mutations in regulatory and / or promoter sequences for expressing a polypeptide that result in altered expression levels of a polypeptide according to the invention provide "homologs of nucleotide sequences". Similarly, substitutions, deletions or additions of nucleic acids in the polynucleotides of the present invention provide "homologs" of nucleotide sequences. In various embodiments, "homologs" of nucleic acid sequences have substantially the same biological activity as the corresponding reference gene, i.e., genes homologous to natural genes will encode proteins that have the same biological activity as the corresponding proteins encoded by the naturally occurring genes. Typically, the homologue of a gene has at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the gene. These percentages are only statistically significant, and the differences between two nucleotide sequences can be randomly distributed and can be distributed over the entire sequence length.
[0070] As used herein, the phrase "transformed cell" refers to a cell transformed with a DNA vector or plasmid disclosed herein.
[0071] In certain embodiments, the purified compound is at least 60% by weight of the compound of interest. Preferably, the formulation is at least 75% by weight, more preferably at least 90% by weight, most preferably at least 98% by weight of the compound of interest. For example, the purified compound is a compound having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99% or 100% (w / w) of the desired compound by weight. Purity is measured by any suitable standard method, for example, by column chromatography, thin layer chromatography or high performance liquid chromatography (HPLC) analysis.
[0072] As used herein, "decrease" refers to a negative change and "increase" refers to a positive change, wherein the negative or positive change is at least 0.001%, 0.01%, 0.1%, 0.5%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.
[0073] As used herein, the term "effective amount" is used to refer to the amount of a compound or composition that is capable of inhibiting, preventing or ameliorating a condition in a subject when administered to or in contact with an organism. In other words, the amount is "effective" when administered to or in contact with an organism. The actual amount will vary depending on many factors, including but not limited to the severity of the condition and the route of administration.
[0074] In one embodiment, "treatment" of any cancer refers to ameliorating the cancer (i.e., inhibiting or slowing the development of the disease or at least one of its clinical symptoms). In another embodiment, "treatment" refers to improving at least one physical parameter that may not be perceptible to the subject. In yet another embodiment, "treatment" refers to modulating the cancer, either physically (e.g., stabilization of perceptible symptoms), physiologically (e.g., stabilization of physical parameters), or both. In yet another embodiment, "treatment" refers to delaying the onset of cancer.
[0075] As used herein, the terms "reduce," "inhibit," "block," "prevent," "mitigate," or "alleviate" when referring to a polypeptide or other compound means that the polypeptide or other compound reduces the incidence, severity, size, volume, or associated symptoms of a cancer by at least about 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 22.5%, 25%, 27.5%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, or 100% compared to how the cancer would normally exist without the administration of the polypeptide or other compound or composition comprising the polypeptide or other compound.
[0076] The statement of a list of chemical groups in the definition of any variable herein includes defining the variable as any single group or combination of the listed groups. The statement of an embodiment of any variable or aspect herein includes the embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0077] All references cited herein are hereby incorporated by reference in their entirety.
[0078] Compositions that reduce the interaction between Shh and SURF4
[0079] The present disclosure relates to various compounds that inhibit the interaction between Shh and SURF4 in a subject, particularly a subject suffering from cancer, or delay the onset of cancer in a subject. In certain embodiments, the methods according to the present invention comprise administering to a subject suffering from or diagnosed with cancer a therapeutically effective amount of a novel composition comprising a polypeptide and / or a different molecule (e.g., a macromolecule). "Therapeutically effective amount" refers to an amount or dosage sufficient to bring the desired therapeutic or preventive benefit to a patient in need of such treatment for a specified cancer.
[0080] In certain embodiments, the novel composition inhibits the interaction of Shh with SURF4 and comprises an effective amount of a polypeptide having an amino acid sequence comprising SEQ ID NO: 6-8 or SEQ ID NO: 10. In addition, an effective amount of the composition comprises a polypeptide having an amino acid sequence having 90% or greater identity with SEQ ID NO: 6-8 or SEQ ID NO: 10.
[0081] In certain embodiments, the vector can be easily prepared using methods available in the art. The transformation vector comprises one or more nucleotide sequences that can be transcribed into RNA molecules and are substantially homologous and / or complementary to one or more nucleotide sequences encoding the amino acid sequence SEQ ID NO: 6-8 or SEQ ID NO: 10. The recombinant nucleic acid vector can be, for example, a linear or closed circular plasmid. The vector system can be a single vector or plasmid, or two or more vectors or plasmids that together contain all nucleic acids. The vector can encode the following nucleotide sequence: the nucleotide sequence encodes a polypeptide that targets Shh, SURF4 and / or Shh-SURF4 interactions.
[0082] In certain embodiments, the novel compositions may include molecules such as glycosaminoglycans (GAGs). In certain embodiments, the GAGs are, for example, heparin, heparin sulfate, heparin sulfate proteoglycans (HSPGs), or chondroitin sulfate proteoglycans (CSPGs).
[0083] The effective amount or dosage of the polypeptide or other molecule (e.g., macromolecule) of the present invention can be determined by conventional methods such as modeling, dose escalation studies or clinical trials, and conventional factors are taken into account, such as the mode or route of administration or drug delivery, the pharmacokinetics of the polypeptide or other (e.g., macromolecule) molecule, the severity and course of cancer, the subject's previous or ongoing treatment, the subject's health status and response to the drug, and the judgment of the treating physician. Examples of dosages are within the following ranges: about 0.001 mg to about 200 mg of polypeptide or other molecule (e.g., macromolecule) per kg of subject body weight per day, preferably about 0.05 mg / kg / day to 100 mg / kg / day, or about 1 mg / kg / day to 35 mg / kg / day, even more preferably about 1 mg / kg / day, 5 mg / kg / day, 10 mg / kg / day or 20 mg / kg / day, in a single dose unit or divided dose units (e.g., BID, TID, QID). For a 70 kg human, an exemplary range of suitable dosage is about 0.05 g / day to about 7 g / day, preferably about 0.07 g / day to about 2.45 g / day, even more preferably about 0.07 g / day, 0.35 g / day, 0.7 g / day or 1.4 g / day.
[0084] In certain embodiments, polypeptide or other molecule (such as macromolecule) can be administered intramuscularly, subcutaneously, intrathecally, intravenously or intraperitoneally by means of infusion or injection. Solutions of polypeptide or other molecule (such as macromolecule) can be prepared in water, optionally mixed with nontoxic surfactant. Under common storage and use conditions, these preparations can contain preservatives to prevent the growth of microorganisms.
[0085] The pharmaceutical dosage form suitable for injection or infusion may include a sterile aqueous solution or dispersion or sterile powder, which contains polypeptides or other molecules (e.g., macromolecules), which are suitable for the temporary preparation of sterile injectable or infusible solutions or dispersions, which are optionally encapsulated in liposomes. Preferably, the final dosage form should be sterile, liquid and stable under manufacturing and storage conditions. The liquid carrier or carrier can be a solvent or liquid dispersion medium, including (e.g.) water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), vegetable oils, non-toxic glycerides, and suitable mixtures thereof. Suitable fluidity can be maintained by (e.g.) the formation of liposomes, by maintaining the desired particle size in the case of dispersions, or by using surfactants. The effects of microorganisms can be prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. In many cases, isotonic agents such as sugars, buffers, or sodium chloride are preferably included. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0086] Sterile injectable solutions are prepared by incorporating the desired amount of a polypeptide or other molecule (e.g., macromolecule) in an appropriate solvent as described herein along with various other ingredients listed herein (as required), preferably followed by filtered sterilization. In the case of sterile powders (for the preparation of sterile injectable solutions), the preferred methods of preparation are vacuum drying and freeze drying techniques, which produce a powder of the active ingredient plus any additional desired ingredient present in a previously sterile-filtered solution.
[0087] The compositions of the present invention can also be orally administered in combination with pharmaceutically acceptable carriers such as inert diluents or assimilable edible carriers. They can be enclosed in hard or soft shell gelatin capsules, compressed into tablets, or directly incorporated into the food of the subject's diet.
[0088] For oral therapeutic administration, polypeptides or other molecules (e.g., macromolecules) can be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, lozenges, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain, for example, at least 0.1% of the polypeptides or other molecules of the invention. Of course, the percentage of the polypeptides or other molecules (e.g., macromolecules) of the invention in the compositions and preparations can vary. The amount of the polypeptide or other molecule (e.g., macromolecule) in such therapeutically useful compositions is such that an effective dosage level can be obtained.
[0089] Tablets, troches, pills, capsules, etc. may also contain one or more of the following: binders such as gum tragacanth, gum arabic, corn starch or gelatin; excipients such as dicalcium phosphate; disintegrants such as corn starch, potato starch, alginic acid, etc.; lubricants such as magnesium stearate; and sweeteners such as sucrose, fructose, lactose or aspartame, or flavorings such as peppermint, wintergreen oil or cherry flavoring may be added.
[0090] When the dosage unit form is a capsule, the capsule may contain, in addition to materials of the above type, a liquid carrier such as a vegetable oil or polyethylene glycol.
[0091] Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For example, tablets, pills, or capsules may be coated with gelatin, wax, shellac, or sugar, etc. Syrups or elixirs may contain polypeptides or other molecules (e.g., macromolecules), sucrose or fructose as sweeteners, methyl and propylparabens as preservatives, dyes, and flavorings such as cherry or orange flavors.
[0092] Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
[0093] In addition, polypeptide or other molecules (e.g., macromolecules) can be introduced into sustained-release preparations and devices. For example, polypeptide or other molecules (e.g., macromolecules) can be introduced into delayed-release capsules, delayed-release tablets, delayed-release pills, delayed-release polypeptide or other molecules (e.g., macromolecules) or nanoparticles.
[0094] The pharmaceutical composition for topical application of polypeptide or other molecules (such as macromolecules) to epidermis (mucosal or skin surface) can be formulated into ointment, cream, lotion, gel or transdermal patch. This transdermal patch can include penetration enhancers, such as linalool, carvacrol, thymol, citral, menthol, t-anethole, etc. Ointment and cream can (for example) include aqueous or oily base, and add suitable thickener, gelling agent, coloring agent, etc. Lotion and cream can include aqueous or oily base, and usually also include one or more emulsifiers, stabilizers, dispersants, suspending agents, thickeners, coloring agents, etc. Gel preferably includes aqueous carrier matrix, and includes gelling agent, such as cross-linked polyacrylic acid polymer, derived polysaccharide (such as carboxymethyl cellulose), etc.
[0095] Pharmaceutical compositions suitable for topical administration in the oral cavity (e.g., buccal or sublingual administration) include lozenges comprising the composition in a flavored base such as sucrose, acacia or tragacanth; pastilles comprising the composition in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. Pharmaceutical compositions for topical administration in the mouth may contain a penetration enhancer, if desired.
[0096] Available solid carriers include finely divided solids, such as talc, clay, microcrystalline cellulose, silicon dioxide, aluminum oxide, etc. Other solid carriers include nontoxic polymer nanoparticles or micron particles. Available liquid carriers include water, alcohol or glycol or water / alcohol / glycol mixtures, wherein polypeptides or other molecules (such as macromolecules) can be dissolved or dispersed in the liquid carrier at an effective level (optionally with the aid of nontoxic surfactants). Adjuvants such as spices and other antimicrobial agents can be added to optimize the properties of a given use. The resulting liquid composition can be applied by an absorbent pad, used to impregnate bandages and other dressings, or sprayed onto the affected area using a pump type or aerosol sprayer.
[0097] Thickening agents such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials may also be employed with the liquid carrier to form spreadable pastes, gels, ointments, soaps, etc., for application directly to the skin of the user.
[0098] Examples of useful dermatological compositions that can be used to deliver polypeptides or other molecules (e.g., macromolecules) to the skin are known in the art; for example, see patents to Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157), and Wortzman (U.S. Pat. No. 4,820,508), all of which are incorporated herein by reference.
[0099] The concentration of the polypeptide or other molecules (e.g., macromolecules) of the present invention in such preparations can vary widely depending on the nature of the preparation and the intended route of administration. For example, the concentration of the polypeptide or other molecules (e.g., macromolecules) in liquid compositions such as lotions may preferably be about 0.1% to 25% by weight, or more preferably about 0.5% to 10% by weight. The concentration in semi-solid or solid compositions such as gels or powders may preferably be about 0.1% to 5% by weight, or more preferably about 0.5% to 2.5% by weight.
[0100] Pharmaceutical compositions for spinal administration or injection into amniotic fluid may be provided in unit doses in the form of ampoules, prefilled syringes, small volume infusions, or multi-dose containers, and may contain added preservatives. Compositions for parenteral administration may be suspensions, solutions, or emulsions, and may contain excipients such as suspending agents, stabilizers, and dispersing agents.
[0101] Pharmaceutical compositions suitable for rectal administration include a combination of a polypeptide or other molecule (e.g., macromolecule) of the invention and a solid or semisolid (e.g., cream or paste) carrier or vehicle. For example, such rectal compositions may be provided as unit dose suppositories. Suitable carriers or vehicles include cocoa butter and other materials commonly used in the art.
[0102] According to one embodiment, the pharmaceutical composition of the present invention suitable for vaginal administration is provided in the form of vaginal suppositories, tampons, creams, gels, pastes, foams or sprays, which comprise a combination of polypeptides of the present invention or other molecules (e.g., macromolecules) with carriers known in the art. Alternatively, the composition suitable for vaginal administration can be delivered in liquid or solid dosage forms.
[0103] The present invention also includes pharmaceutical compositions suitable for intranasal administration. Such intranasal compositions comprise polypeptides of the present invention or other molecules (e.g., macromolecules) in a carrier and suitable application devices to deliver liquid sprays, dispersible powders or drops. Drops can be prepared with aqueous or non-aqueous substrates that also comprise one or more dispersants, solubilizers or suspending agents. Liquid sprays are conveniently delivered from pressurized boxes, insufflators, sprayers or other convenient devices that deliver aerosols comprising polypeptides or other molecules (e.g., macromolecules). Pressurized boxes include suitable propellants, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gases well known in the art. Aerosol dosage can be controlled by providing a valve to deliver a metered amount of polypeptides or other molecules (e.g., macromolecules).
[0104] The polypeptide or other molecule (eg, macromolecule) can be combined with an inert powdered carrier and inhaled or insufflated by the subject.
[0105] Pharmaceutical compositions for administration by inhalation or insufflation may be provided as dry powder compositions, for example a powder mix of a polypeptide or other molecule (e.g. a macromolecule) and a suitable powder base such as lactose or starch. Such powder compositions may be provided in unit dosage form, for example, in capsules, cartridges, gelatin cartridges or blister packs, from which the powder may be administered with the aid of an inhaler or insufflator.
[0106] The exact amount (effective dose) of a polypeptide or other molecule (e.g., macromolecule) varies from subject to subject, depending on, for example, the species, age, weight, and overall or clinical condition of the subject, the severity or mechanism of any cancer being treated, the specific agent or carrier used, the method and schedule of administration, etc. The therapeutically effective dose can be determined empirically by conventional methods known to those skilled in the art. See literature, for example, The Pharmacological Basis of Therapeutics, edited by Goodman and Gilman, Macmillan Publishing Co., New York. For example, the effective dose can initially be estimated by in vivo testing or in a suitable animal model. Animal models can also be used to determine suitable concentration ranges and routes of administration. This information can then be used to determine useful doses and routes for administration to humans. Methods for extrapolating effective doses in mice and other animals to humans are known in the art; for example, see U.S. Patent No. 4,938,949, which is incorporated herein by reference. In addition, the therapeutic dose can be selected by analogy to the dose of a similar therapeutic agent.
[0107] The specific mode of administration and dosage regimen can be selected by the attending clinician considering the details of the case (e.g., subject, disease, disease state involved, and whether treatment is prophylactic). Treatment may include daily or multiple daily doses of the compound over a period of several days to several months or even several years.
[0108] However, generally suitable dosages can be in the range of about 0.001 mg / kg body weight to about 100 mg / kg body weight per day, preferably about 0.01 mg / kg body weight to about 100 mg / kg body weight per day, more preferably about 0.1 mg / kg body weight to about 50 mg / kg body weight per day, or even more preferably about 1 mg / kg body weight to about 10 mg / kg body weight per day. For example, suitable dosages can be about 1 mg / kg body weight, 10 mg / kg body weight or 50 mg / kg body weight per day.
[0109] Polypeptides or other molecules (eg, macromolecules) may be conveniently administered in unit dosage form containing, for example, from about 0.05 mg to about 10,000 mg, from about 0.5 mg to about 10,000 mg, from about 5 mg to about 1000 mg, or from about 50 mg to about 500 mg of active ingredient per unit dosage form.
[0110] The polypeptide or other molecule (eg, macromolecule) may be included in the composition in a concentration range that is therapeutically useful and effective, as determined by conventional methods well known in the medical and pharmaceutical arts.
[0111] The polypeptide or other molecule (e.g., macromolecule) may conveniently be presented in a single dose or divided doses administered at appropriate intervals, for example, once a day or as two, three, four or more sub-doses per day. The sub-doses themselves may be further divided, for example, into a number of discrete, loosely spaced administrations; for example, multiple inhalations from an insufflator.
[0112] Optionally, the pharmaceutical composition of the present invention may include one or more other therapeutic agents, for example as a combination therapy. As determined by conventional methods well known in the medical and pharmaceutical fields, the one or more other therapeutic agents included in the composition are within a therapeutically useful and effective concentration range. The concentration of any particular other therapeutic agent may be within the same range as that of the agent typically used as a monotherapy, or if there is a synergistic effect when combined with the polypeptide of the present invention or other molecules (e.g., macromolecules), the concentration may be lower than that of a typical monotherapy.
[0113] Methods for inhibiting the interaction between Shh and SURF4
[0114] The present invention relates to treating various types of cancer in a subject by inhibiting the interaction between Shh and SURF4, particularly ligand-dependent cancer types, including (for example) gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, ovarian cancer and endometrial cancer, breast cancer, prostate cancer, lung cancer, melanoma, glioma, other extracutaneous tumors or any combination thereof.
[0115] In certain embodiments, polypeptides and / or other molecules (eg, macromolecules) may be used in cancer treatment.
[0116] Methods for treating or preventing cancer can be performed in any subject, such as a mammal, including humans. Such methods include administering an effective amount of a polypeptide or other molecule (e.g., macromolecule) of the present invention to a subject in need of such prevention or treatment of cancer. The polypeptide or other molecule (e.g., macromolecule) can be administered in the form of a pharmaceutical composition of a polypeptide, molecule (e.g., macromolecule) or a combination thereof.
[0117] In certain embodiments, the present invention provides a method for inhibiting the interaction between Shh and SURF4 by mutating a nucleotide sequence encoding Shh and / or SURF4 using CRISPR / Cas9 technology. In a preferred embodiment, the amino acid residues E50, D53, D56 of human SURF4 or any combination thereof are mutated, or the nucleotide sequence encoding the amino acid residues E50, D53, D56 of human SURF4 or any combination thereof is mutated. In a preferred embodiment, 1, 2, 3, 4, 5, 6 or 7 residues at positions 32-38 of human Shh are mutated, or the nucleotide sequence encoding 1, 2, 3, 4, 5, 6 or 7 residues at positions 32-38 of human Shh are mutated.
[0118] The method may further comprise altering the expression of SURF4 or Shh to achieve downregulation or inhibition of one or more target amino acids or to achieve inhibition of the interaction of Shh with SURF4.
[0119] In certain embodiments, the transcriptional inhibition of the target gene is mediated by a gene inhibitor that exhibits substantial sequence identity to a DNA sequence of a target nucleotide sequence or its complementary sequence, including a promoter sequence or SURF4 and / or Shh. The inhibition of the target gene or amino acid of the present invention is sequence-specific and may include insertions, deletions, and single point mutations relative to the target sequence.
[0120] Materials and methods
[0121] Constructs, reagents, cell culture, transfection, and immunofluorescence
[0122] HeLa cells and HEK293T cell lines were provided by the University of California, Berkeley Cell Culture Facility and confirmed by short tandem repeat analysis. All cell lines tested negative for mycoplasma contamination. HeLa and HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum and 1% penicillin-streptomycin mixture (Invitrogen). HEK293Trex and HEK 293Trex SURF4 KO cell lines were maintained in Gibco DMEM containing 5 μg / ml blasticidin and 10% FBS.
[0123] Plasmids, siRNAs, and antibodies are described herein. siRNAs or DNA constructs were transfected into HeLa cells or HEK293T cells and immunofluorescence was performed as previously described (27). Images were acquired using a Zeiss Axio Observer Z1 microscope system (Carl Zeiss, Germany) equipped with an ORCA Flash 4.0 camera (Hamamatsu, Japan) or a Leica STED TCS SP5II confocal laser scanning microscope (Leica, Germany). To quantify the colocalization between ERGIC53 and GM130, the GM130-labeled near-nuclear region was manually outlined as the region of interest (ROI) using the freehand selection function of Fiji. To quantify the colocalization between SURF4-HA and GM130 or ERGIC53, the SBP-EGFP-ShhN-labeled near-nuclear region was manually outlined as the ROI in Fiji. To quantify the colocalization between ShhN and GM130, the ShhN-labeled near-nuclear region was manually outlined as the ROI in Fiji. All pixels in the ROI were desaturated. Pearson's R value in the ROI between the two channels was then calculated using Coloc2 in Fiji (without thresholding).
[0124] For CRISPR experiments, sgRNA sequences linked to pX458 (pSpCas9 BB-2A-GFP) plasmids were purchased from GenScript. Transfection was performed with TransitIT-293 (Mirus Bio) according to the manufacturer's instructions. Clonal cell lines were obtained by diluting the cell suspension to a single cell per well and amplifying each well. Genotyping of clonal cell lines was performed by Sanger sequencing of target site PCR amplicons of genomic DNA isolated by the Puregene kit (Quiagene). sgRNAs are as follows: SURF4 targeting exon 1, 5'-AGTCGCGCTGCTCGCTCCAC-3' (SEQ ID NO: 1).
[0125] Retention on Selective Hook (RUSH) Test and Antibody Uptake Test
[0126] RUSH assays were performed as previously described (26). Antibody uptake assays were performed as previously described (53).
[0127] Immunoprecipitation, protein purification, and binding assays
[0128] Immunoprecipitation was performed as described (27). GST-tagged ShhN was expressed as described previously (54). 25-49 and GST-tagged SURF4 1-62 Purification of GST was performed as previously described (54). Peptide binding assays were performed as previously described (27).
[0129] Sample preparation for label-free quantitative MS analysis
[0130] This procedure was performed as described previously ( 26 ).
[0131] In vitro vesicle formation assay
[0132] In vitro vesicle release assays were performed as described previously ( 27 , 55 ).
[0133] Plasmids, siRNA, and antibodies
[0134] cDNAs encoding mouse ShhN, human SURF4, human IGF2, and human XYLT2 were purchased from BGI (Beijing, China). The cDNA encoding ShhN with a C-terminal 3x HA tag was generated by standard molecular cloning methods. 1-198 , Shh with a GST tag at the C-terminus 25-49 , IGF2 with 3x HA tag at C-terminus, SURF4 with 3x HA tag at C-terminus, SURF4 with 3x Myc tag at C-terminus, SURF4 with GST tag at N-terminus 49-60 , N-terminally 3xMyc-tagged XYLT2, Str-KDEL_SBP-EGFP-ShhN 25-198 , Str-KDEL_SBP-EGFP-Shh FLPlasmids encoding truncated forms of ShhN, Str-KDEL_SBP-EGFP-E-cadherin, and ShhN were generated. The N-terminus of the SBP-EGFP tag was followed by a signal sequence derived from IL-2 (56). Plasmids encoding mutant forms of ShhN and SURF4 were generated by QuickChange II site-directed mutagenesis using plasmids encoding ShhN-HA, Str-KDEL_SBP-EGFP-ShhN, and SURF4-3xMyc as templates. Plasmids encoding siRNA-resistant SURF4-HA were generated by QuickChange II site-directed mutagenesis using plasmids encoding SURF4-HA as templates.
[0135] siRNAs against SURF4 and XYLT2 were purchased from Ribo-bio (Guangzhou, China). The target sequences of the two siRNAs against SURF4 were GCAGGAACTTCGTGCAGTA (SEQ ID NO: 2) and GCATCCGTATGTGGTTCCA (SEQ ID NO: 3), respectively. The target sequences of the two siRNAs against XYLT2 were CTGGTAGTGTGGAGCTTCA (SEQ ID NO: 4) and GCGTGCACCTGTATTTCTA (SEQ ID NO: 5), respectively. Commercially available antibodies were rabbit anti-HA (Cell Signaling, catalog number 3724), mouse anti-HA (Biolegend, catalog number 901501), mouse anti-Myc (Cell Signaling, catalog number 2276), mouse anti-PDI (Enzo, catalog number ADI-SPA-891-F), sheep anti-TGN46 (BIO-RAD, catalog number AHP500G), rabbit anti-ERGIC53 (Sigma-Aldrich, catalog number E1031) and mouse anti-GM130 (BD Bioscience, catalog number 610823) for immunofluorescence analysis. Rabbit anti-SEC22B antibody and rabbit anti-ERGIC53 antibody for immunoblot analysis were kindly provided by Professor Randy Schekman (University of California, Berkeley, California, USA). Rabbit anti-SURF4 antibody was kindly provided by Professor Xiaowei Chen (Peking University, China). Rabbit anti-GFP antibody was kindly provided by Professor Robert Qi (Hong Kong University of Science and Technology, Hong Kong SAR, People's Republic of China).
[0136] Retention on selective hook (RUSH) assay, antibody uptake assay, and permeabilized cell assay
[0137] RUSH assays were performed by treating HeLa cells transfected with plasmids encoding Str-KDEL and different forms of SBP-EGFP-ShhN for the indicated times in complete medium containing 40 μM biotin (Sigma-Aldrich) and 100 ng / μl cycloheximide (Sigma-Aldrich). TM Gold antifade mounting medium (Invitrogen), and cells were mounted on slides with 4% PFA for microscopic analysis.
[0138] To analyze the secretion of ShhN, HEK293T cells transfected with plasmids encoding Str-KDEL and different forms of SBP-EGFP-ShhN were treated in medium without FBS supplemented with 100 ng / μl cycloheximide and 40 μM biotin for the indicated time. Secreted proteins were then collected by TCA precipitation. Cells were collected and lysed with HKT buffer (100 mM KCl, 20 mM Hepes, pH 7.2, 0.5% Triton X-100). Bound proteins and cell lysates were analyzed by immunoblotting.
[0139] For antibody uptake assays, HeLa cells were treated with (or without) 2.5 mM xyloside in complete medium. 24 hours after xyloside treatment, cells were transfected with the protein encoding Str-KDEL_SBP-EGFP-HA-Shh FL The cells were transfected with plasmids. On the second day after xyloside treatment, the cells were incubated for 1 hour in complete medium without biotin or containing 40 μM biotin and 100 ng / μl cycloheximide. After incubation, mouse anti-HA antibody was added to the incubation medium at a dilution of 1:200 to mark the ShhN fusion construct that had been delivered to the cell surface. After incubation at 37°C for another 40 min, the cells were fixed with 4% paraformaldehyde in PBS for 15 min, and then standard immunofluorescence procedures were performed using rabbit anti-GFP antibody as the primary antibody.
[0140] Permeabilization assays were performed as described previously (57). Briefly, HeLa cells transfected with Str-KDEL_SBP-EGFP-ShhN were treated with 0.04 mM biotin for 4 min at 37°C and then incubated in cold KOAc buffer (110 mM KOAc, 2 mM Mg(OAc)). 2, 20mM Hepes, pH 7.2) three times. Then, the cells were permeabilized for 6 min at room temperature with a KOAc buffer solution of 0.03mg / mL digitonin. The permeabilized cells were washed with cold KOAc buffer. Incubated on ice with cold 0.5M KOAc buffer for 5 min, then washed three times in cold KOAc buffer to remove cytoplasmic proteins, and then the permeabilized cells were incubated at 37°C in KOAc buffer containing 2mg / ml rat liver cytosol, 0.04mM biotin, 500μM GDP / GTPγS and ATP regeneration system (40mM creatine phosphate, 0.2mg / mL creatine phosphate kinase and 1mM ATP) for 15 min. The cells were then washed with cold KOAc buffer, fixed, and stained with specific antibodies.
[0141] Immunoprecipitation, protein purification, and binding assays
[0142] Immunoprecipitation of HA-tagged ShhN was performed by incubating 200 ml of 0.5 mg / ml HKT buffer solution of cell lysate from HEK293T cells transfected with HA-ShhN with 10 μl of dense anti-HA agarose affinity beads overnight at 4° C. After incubation, the beads were washed 4 times with 1 ml HK buffer (100 mM KCl, 20 mM Hepes, pH 7.2) and the bound material was analyzed by Coomassie brilliant blue staining and immunoblotting.
[0143] HEK293T cells co-transfected with plasmids encoding the indicated proteins were cultured in a medium containing 2 mM dithiobis[succinimidyl propionate] (DSP) and 2 mM CaCl 2 The cells were then quenched with 25 mM Tris-HCl (pH 7.5) to perform Myc-tagged SURF4 or Myc-tagged SURF4 ED-AA HA-tagged mouse ShhN or mouse ShhN △33-39 Binding assay between 200 ml of 0.5 mg / ml cell lysate and 10 μl of dense anti-HA agarose affinity beads were incubated overnight at 4°C with mixing. After incubation, the beads were washed 4 times with 1 ml HK buffer (100 mM KCl, 20 mM Hepes, pH 7.2) and the bound substances were analyzed by immunoblotting.
[0144] GST-tagged ShhN was expressed as described previously (58). 25-49 and GST-tagged SURF4 49-60 10 μl of ShhN with about 5 μg of GST-tagged 25-49The dense GSH beads of were subjected to GST precipitation assay. The beads were incubated with 200 ml of 0.5 mg / ml HKT buffer solution of cell lysate from HEK293T cells transfected with HA-SURF4 at pH 6.0 or 7.2 overnight at 4°C with mixing. After incubation, the beads were washed three times with 500 ml HKT buffer and twice with 500 ml HK buffer, and the bound material was analyzed by immunoblotting.
[0145] Peptide binding assays were performed as previously described (59). The synthetic CW peptide (KRRHPKKC; SEQ ID NO: 6), CW MT Peptide (AAAHPAAC; SEQ ID NO: 9), SURF4 49-61 Peptide (SEQRDYIDTTWNC; SEQ ID NO:10), SURF4 49-60 The peptide (SEQRDYIDTTWN; SEQ ID NO: 12) or the RRFR peptide (VRRFRYPERPC; SEQ ID NO: 11) was purchased from GenScript and coupled to thiopyridone-Sepharose 6B beads (Sigma-Aldrich) via an additional C-terminal cysteine residue. For binding experiments, 2 μg of purified GST-tagged SURF4 was added in a total volume of 15 ml of HK buffer. 49-60 or Shh 25-49 -GST was pre-incubated at 4°C for 30 min. After incubation, 15 ml of buffer containing about 5 μl of beads containing 5 nmol of peptide was added to the reaction mixture for 1 hour at 4°C. The beads were washed four times with 500 ml of HK buffer and analyzed by immunoblotting.
[0146] Label-free quantitative mass spectrometry
[0147] Mass spectrometry was performed to identify proteins involved in Shh secretion. Plasmids encoding Shh-HA or IGF2-HA were transfected into HEK293T cells, immunoprecipitated, and stained with Coomassie Brilliant Blue (Bio-Safe TM The bound proteins were analyzed by Coomassie-G250 staining. The protein gel was cut into small pieces and washed with 25 mM NH 4 HCO 3 The gel segments were then shrunk with acetonitrile at room temperature for 15 min and dried by rapid vacuum extraction. The dried protein gel pieces were washed with 0.1 M NH 4 HCO 3The mixture was reduced at 55°C for 45 min and washed with 0.1 M NH 4 HCO 3 The alkylation was carried out at room temperature in the dark for 45 min. Then, the gel pieces were washed with 0.1 M NH 4 HCO 3 The cells were washed and the shrinking and drying steps were repeated. Then, 50 mM NH 4 HCO 3 The proteins were digested on ice for 45 min and then lysed in 50 mM NH 4 HCO 3 Incubate at 37°C overnight. 4 HCO 3 The peptides were extracted with 60% acetonitrile containing 5% formic acid. The samples were then dried using a rapid vacuum. The dried peptides were dissolved in 0.1% trifluoroacetic acid to remove the surfactant, desalted using a Pierce C18 spin column, and dried by rapid vacuum. Finally, the resulting peptides were analyzed by mass spectrometry. Protein identification was then performed using tandem mass spectrometry and label-free quantification was performed using ProteomeDiscoverer. Proteins associated with Shh or IGF2 were identified by comparing the peak intensities of the proteins identified in the experimental and control groups.
[0148] In vitro vesicle formation assay
[0149] In vitro vesicle release assays were performed as described previously (59, 60). Briefly, approximately 90% confluent HEK293T cells grown in a 10 cm dish were permeabilized on ice for 5 min in 3 ml of ice-cold KOAc buffer containing 40 mg / ml digitonin on day 1 after transfection with plasmids encoding different forms of ShhN with an HA tag, and then semi-intact cells were pelleted by centrifugation at 300 × g for 3 min at 4°C. The cell pellets were washed twice with 1 ml of KOAc buffer and resuspended in 100 ml of KOAc buffer. Budding assays were performed by incubating semi-intact cells (approximately 0.02 OD / reaction) with 2 mg / ml of rat liver cytosol in a 100 ml reaction mixture containing 200 mM GTP and an ATP regeneration system in the presence or absence of 0.5 mg Sar1A (H79G). After incubation at 32°C for 1 hour, the reaction mixture was centrifuged at 14,000 × g to remove cell debris and large membranes. The medium-speed supernatant was then centrifuged at 100,000 × g to precipitate small vesicles. The pellet fraction was then analyzed by immunoblotting. For density gradient flotation experiments, the pellet fraction was resuspended in 100 ml of 35% OptiPrep and superimposed with 700 ml of 30% OptiPrep and 30 ml of KOAc buffer. The sample was centrifuged at 55,000 rpm at 4°C for 2 hours in a TLS55 rotor in a Beckman ultracentrifuge. After centrifugation, the fractions at the top and bottom of the test tube were collected and the top fractions were analyzed by SDS-PAGE and immunoblotting.
[0150] Isothermal Titration Calorimetry (ITC)
[0151] We used a commercially available isothermal titration calorimeter (PEAQ-ITC system, MicroCal, Malvern Panalytical, UK) for titration experiments. In these experiments, 500 μM of CW peptide was diluted in binding buffer (10 mM PBS, 0.5 mM HEPES, 6.3 mM sorbitol, 1.75 mM KOAc, 25 μM Mg(OAc) 2, 25 μM BSA, 0.003% Triton, pH 7.2) was loaded into the syringe of the ITC instrument, and a solution of 50 μM GST-SURF4 (49-60) in the same buffer was loaded into the calorimetric cell. Similarly, GST was titrated with CW peptide. During each ITC experiment, 19 injections of CW peptide into the calorimetric cell were performed, each injection lasting 4 s and the time between injections was 150 s. The volume of each injection was 2 μL and the stirring speed was maintained at 750 rpm. Control experiments were also performed, such as peptide titration buffer and buffer titration protein to account for nonspecific interactions and dilution heat. The data were fitted to a set of site models using MicroCal PEAQ-ITC analysis software to obtain the binding constant (K d ).
[0152] All patents, patent applications, provisional applications, and publications referenced or cited herein are hereby incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.
[0153] The following are examples of the process of implementing the present invention. These examples should not be construed as limiting. Unless otherwise stated, all percentages are weight percentages, and all solvent mixing ratios are volume ratios.
[0154] Example 1—ER export of ShhN depends on its Cardin-Weintraub (CW) motif
[0155] As a first step, to avoid potential complications from post-translational modification pathways, we examined the N-terminal fragment (ShhN) without cholesterol modification. The selective retention on hook (RUSH) transport assay (23) was performed to analyze surface delivery in a synchronous manner. In the RUSH assay, HeLa cells were transfected with a plasmid encoding a mouse N-terminal Shh fragment with the signal peptide removed (aa: 25-198) fused downstream of EGFP and streptavidin binding peptide (SBP) with an N-terminal signal peptide derived from IL-2 (SBP-EGFP-ShhN or SBP-EGFP-ShhN). 25-198 , Fig. 7A ). The plasmid also encodes streptavidin fused to a C-terminal ER retention signal (Lys-Asp-Glu-Leu; Str-KDEL). Due to the binding between streptavidin and SBP, SBP-EGFP-ShhN is retained in the ER and colocalizes with the ER marker protein disulfide isomerase (PDI) ( Figure 7BFigure BE). When cells were incubated with biotin, SBP was released from streptavidin, thereby releasing SBP-EGFP-ShhN from the ER ( Figure 7B Picture FI, Fig.7D Image LM). 15min after biotin treatment ( Figure 7B Image FI) or 30min( Fig.7D Figure L). In most cells, SBP-EGFP-ShhN protein was localized in the juxtanuclear region. In three independent experiments, we counted 100 random cells showing the juxtanuclear form of ShhN 15 min after biotin treatment and found that ShhN colocalized with the Golgi marker TGN46 in all cells ( Figure 7C ). Therefore, in the following analysis, it is believed that the juxtanuclear ShhN is located in the Golgi region. After 30 minutes of biotin treatment, in about 80% of the cells, the SBP-EGFP-ShhN protein was localized in the juxtanuclear Golgi region ( Fig.7D Image L and Fig. 7E Quantitative results in ). After biotin treatment, the RUSH construct (SBP-EGFP) that does not contain the ShhN sequence was retained in the ER in more than 95% of the cells ( Fig.7D Picture NO and Fig. 7E Quantitative results in ( ). These results indicate that the RUSH assay is sufficiently powerful to analyze the kinetics of ER-to-Golgi transport of ShhN. These results also indicate that ShhN contains a motif that drives efficient export of ShhN from the ER.
[0156] Next, we generated a series of RUSH constructs containing truncated forms of Shh. We found that SBP-EGFP-ShhN 25-111 , SBP-EGFP-ShhN 25-68 , SBP-EGFP-ShhN 25-49 Efficient export from ER to Golgi apparatus ( Fig.7D Pictures QS, WY and Fig. 7E ). In contrast, SBP-EGFP-ShhN 112-198 , SBP-EGFP-ShhN 69-111 , SBP-EGFP-ShhN 25-32 Retention in ER Fig.7D Picture TV, Z-AB and Fig. 7E ), indicating that residues 33–49 in ShhN are important for ER export ( Figure 7F Indeed, loss of these residues in ShhN causes defects in ER-to-Golgi transport ( Fig.7D Picture AC-AE and Fig. 7EInterestingly, we found that after biotin treatment, Shh residues 33-49 fused to SBP-EGFP (SBP-EGFP-Shh 33 -49 ) was delivered from the ER to the Golgi with similar efficiency as SBP-EGFP-ShhN ( Figure 1A Image AD and Figure 1B ), indicating that these residues are sufficient to enable SBP-EGFP to leave the ER. Further analysis showed that residues 33-39 in mouse ShhN are sufficient to enable SBP-EGFP to leave the ER, while residues 40-49 are not. Figure 1A Pictures EH and Figure 1B Quantitative results in ).
[0157] The N-terminus of Shh is highly conserved. Cross-species sequence alignment of this region in mouse ShhN (amino acids 33-49) revealed a conserved KRRHPKK (SEQ ID NO:8) or RRRHPKK (SEQ ID NO:7) motif, known as the Cardin-Weintraub (CW) motif (B'B'B'XXB'B', where B' represents a basic amino acid (e.g., arginine or lysine) and X represents any amino acid) ( Figure 1C The CW motif is predicted to be a heparin-binding domain that plays a role in protein-glycosaminoglycan (GAG) interactions (24). Substitution of charged amino acids within this motif with alanine causes defects in ER-to-Golgi transport in the RUSH assay ( Figure 1D Image KP and Figure 1E Quantitative results in ( ). We therefore investigated whether this motif is important for the release of ShhN into the extracellular environment. To test this, we added an HA tag to the C-terminus of SBP-EGFP-ShhN and measured the secretion efficiency by immunoblotting using an antibody against the HA tag. This analysis showed that SBP-EGFP-ShhN-HA was secreted into the culture medium in a biotin-dependent manner ( Figure 1F , compare lanes 1 and 2). Mutation of charged amino acids in the CW motif significantly reduced secretion efficiency ( Figure 1F , compare lanes 2 and 4; and Figure 1G These results suggest that the CW motif plays an important role in the export of ShhN from the ER and its ultimate secretion from the cell. We noticed that the mobility of SBP-EGFP-ShhN-HA in the culture medium was slightly different from that in the cell lysate ( Figure 1F , compare lanes 2 and 5). The shift in mobility may be caused by altered post-translational modifications.
[0158] Example 2—The CW motif is important for packaging of ShhN into COPII vesicles
[0159] To analyze whether the CW motif is important for the packaging of ShhN into COPII vesicles, we reconstituted the vesicular release of ShhN in HEK293T cells ( Figure 1H HEK293T cells transfected with 3xHA-tagged ShhN (ShhN-HA) were permeabilized by digitonin. After permeabilization, semi-intact cells were washed with buffer to remove endogenous cytoplasmic proteins. Semi-intact cells were then incubated with rat liver cytosol (RLC), GTP and ATP regeneration system (ATPrS) at 30°C in the presence or absence of Sar1A's GTP hydrolysis-deficient mutant form (H79G). Released vesicles were then isolated by centrifugation and analyzed by immunoblotting ( Figure 1H ). SAR1A(H79G) inhibited COPII-dependent ER export (25) and prevented vesicle capture of the canonical COPII cargo proteins SEC22B and ERGIC53 (26, 27). In contrast, SAR1A(H79G) did not affect vesicular release of the cargo protein TGN46 derived from the trans-Golgi network (TGN), but enhanced membrane association of SEC23A / B (28). GTP hydrolysis by SAR1A allows the release of COPII from the vesicle membrane to maintain efficient COPII vesicle formation. Based on these analyses, we believe that dependence on SAR1A(H79G) is indirect evidence for cargo packaging into COPII vesicles. In the presence of cytosol, ShhN-HA as well as the COPII cargo protein ERGIC53 are efficiently packaged into transport vesicles ( Fig. 1I , compare lanes 1 and 2). When the vesicle formation assay was performed in the presence of Sar1A(H79G), the efficiency of ShhN-HA and ERGIC53 packaging into transport vesicles was greatly reduced ( Figure 1J , compare lanes 2 and 3), providing evidence that most of the ShhN detected in the vesicle fraction is present in COPII vesicles. Residues 33-49 are missing in mouse ShhN ( Figure 1J ) or deletion of the CW motif (residues 33-39) caused a significant decrease in the efficiency of ShhN packaging into vesicles ( Figure 1K and Figure 1L ), while the abundance of ERGIC53 in transport vesicles did not change ( Figure 1M ). Deletion of residues 40-49 did not cause defects ( Figure 1M These results suggest that the CW motif is important for the packaging of ShhN into COPII vesicles.
[0160] Example 3—SURF4 mediates the packaging of ShhN into transport vesicles and regulates ER-to-Golgi trafficking and secretion of ShhN
[0161] Soluble cargo proteins interact indirectly with the cytoplasmic COPII inner layer through transmembrane cargo receptors. To reveal the cargo receptors that bind ShhN for packaging into transport vesicles, we performed immunoprecipitation experiments. Cell lysates from untransfected HEK293T cells (control group) or cells transfected with plasmids encoding HA-tagged ShhN (ShhN group) or HA-tagged insulin-like growth factor-2 (IGF2, IGF2 group) were incubated with beads conjugated with HA antibodies. The immobilized proteins were then eluted and analyzed by SDS-PAGE and Coomassie Brilliant Blue staining ( Fig. 8A , asterisks indicate the location of ShhN-HA or IGF2-HA). Immunoblot analysis confirmed that IGF2-HA and ShhN-HA could be efficiently immunoprecipitated ( Figure 8B ). The eluted proteins were then digested with trypsin and analyzed by mass spectrometry. We identified the following five proteins in the ShhN-HA group that were not identified in the other two groups ( Figure 8C ): betaine-homocysteine S-methyltransferase (BHMT), glutamate receptor 1 (GRIA1), peptidylprolyl cis-trans isomerase B (PPIB), excess site protein 4 (SURF4), and vacuolar protein sorting-associated protein 51 homolog (VPS51). BHMT is a soluble protein and regulates homocysteine metabolism; GRIA1 belongs to the AMPA receptor family; PPIB can help ShhN fold in the ER; VPS51 is involved in retrograde transport from early and late endosomes to the TGN and can regulate the endosomal-to-TGN trafficking of ShhN. SURF4 has been reported to mediate the ER export of soluble proteins, including lipoproteins and proprotein convertase subtilisin / kexin type 9 (PCSK9) (19-21)( Figure 8C ). Therefore, we speculated that SURF4 is a cargo receptor for Shh. To verify the mass spectrometry results, cell lysates from HEK293T cells transfected with a plasmid encoding Myc-tagged SURF4 (SURF4-Myc), or co-transfected with plasmids encoding ShhN-HA and SURF4-Myc, or co-transfected with IGF2-HA and SURF4-Myc were incubated with beads conjugated with HA antibodies. The fixed proteins were then analyzed by immunoblot analysis. The co-immunoprecipitation results showed that SURF4 interacted more strongly with ShhN than with IGF2 ( Fig.8D , compare lanes 2 and 3), thus indicating that SURF4 can serve as a cargo receptor in the ER export of ShhN.
[0162] Next, we performed siRNA knockdown experiments to reduce the expression of SURF4 and analyzed the effect on the ER export of ShhN. Almost all cells transfected with siRNA against SURF4 showed attenuated SURF4 signal ( Figure 2A ). Western blot analysis showed that the level of SURF4 was greatly reduced in knockdown cells ( Figure 2C ). The nuclear staining pattern of SURF4 antibody labeling may be due to nonspecific staining. We found that knockdown of SURF4 caused a kinetic delay in the delivery of SBP-EGFP-ShhN to the Golgi ( Figure 2A and Figure 2B This defect can be reversed by expressing a SURF4 siRNA-resistant construct (SURF4 RS -HA) and is remedied ( Fig.9A and Fig. 9B Quantitative results in Figure 2). Knockdown of SURF4 also caused a kinetic delay in the delivery of SBP-EGFP-tagged mouse ShhN(33-39) to the Golgi apparatus ( Fig. 10A and Fig. 10B We then generated HEK293Trex SURF4 knockout (KO) cells ( Figure 2D ER-to-Golgi trafficking defects were also detected in SURF4 KO cells ( Figure 2E and Figure 2F KO of SURF4 significantly reduced the secretion of ShhN-HA without SBP-EGFP tag ( Figure 2G Increasing the concentration of the plasmid encoding ShhN-HA used for transfection resulted in an increase in the expression level of ShhN-HA ( Figure 2G , compare lanes 4-6 and 10-12), and under each condition, the secretion of ShhN-HA in SURF4 KO cells was greatly reduced ( Figure 2G , compare lanes 1-3 with lanes 7-9). Using an in vitro vesicle formation assay, we found that ShhN-HA was packaged into transport vesicles in a cytosol-dependent manner in HEK293Trex cells and that SAR1A(H79G) reduced the packaging efficiency ( Figure 2H ). Knockout of SURF4 caused a significant decrease in the efficiency of ShhN packaging into transport vesicles, while the packaging efficiency of ERGIC53 in transport vesicles was unchanged ( FIG. 2H to FIG. 2I ,as well as Figure 2J to Figure 2K Quantitative results in ).
[0163] Since SURF4 binds to ShhN more efficiently than to IGF2 ( Fig.8D), we tested whether SURF4 regulates surface delivery of IGF2. We generated a RUSH construct of IGF2 (SBP-EGFP-IGF2). SBP-EGFP-IGF2 was delivered to the Golgi and secreted in a biotin-dependent manner ( Fig.11A Pictures AC and Fig. 11C , compare lanes 1 and 2). In SURF4 knockdown cells, ER-to-Golgi transport and secretion of SBP-EGFP-IGF2 were normal ( Fig.11A Image DF and Fig. 11B Quantitative results in Fig. 11C , compare lanes 2 and 4). These results suggest that SURF4 functions as a cargo receptor to regulate the packaging of ShhN (but not IGF2) into COPII vesicles for delivery to the Golgi apparatus.
[0164] Next, we performed a permeabilized cell assay to analyze the colocalization between SURF4 and ShhN at early time points after biotin treatment. HeLa cells expressing SBP-EGFP-ShhN were incubated with biotin for 4 min and permeabilized with digitonin. Subsequently, the semi-intact cells were washed to remove endogenous cytoplasmic proteins and then incubated with rat liver cytosol in the presence of GDP or GTPγS. After this incubation, COPII components were recruited to punctate structures at the cell periphery (28, 29), and Arf1 was recruited to the juxtanuclear Golgi region in a GTP-dependent manner (30). We found that in the absence of cytosol and biotin, SBP-EGFP-ShhN showed an ER localization pattern after incubation ( Fig.12 Figures AC). When semi-intact cells were incubated with cytosol, biotin, and GDP, SBP-EGFP-ShhN was partially localized in peripheral punctate structures and partially localized in the ER in most cells ( Fig.12 Image D). When permeabilized cells were incubated with cytosol, biotin, and GTPγS, SBP-EGFP-ShhN was partially localized in punctate structures, and the ER pool of ShhN was greatly reduced ( Fig.12 Figure G). Although ShhN punctate structures were detected at the cell periphery after incubation in the presence of GDP or GTPγS, we did not detect accumulation of ShhN in the juxtanuclear Golgi region 15 min after incubation with the cytosol and nucleotides ( Fig.12 Panels D and G). These analyses demonstrate that this assay locks the ER export process to the cargo sorting stage, thus providing a convenient method to accumulate cargo proteins at the ERES and analyze colocalization between cargo proteins and their receptors.
[0165] In the presence of GDP or GTPγS, many punctate structures of SBP-EGFP-ShhN colocalized with SURF4 ( Fig.12 Picture DI, Fig.12 SEC31A is recruited to semi-intact cells in a GTP-dependent manner ( Fig.12 Figures K and N), consistent with previous reports (28, 29). In the presence of GTPγS, many ShhN punctate structures partially overlapped with SEC31A ( Fig.12 Picture MO, Fig.12 (Enlarged views in images O'-P"'), further demonstrating that the transport intermediate is arrested.
[0166] Example 4—SURF4 interacts directly with the CW motif on ShhN at the ER
[0167] Given that the ER export of ShhN depends on its CW motif ( Figures 1A to 1M ), we next tested whether this signal mediates interaction with SURF4. 25-49 (which contains a CW motif in an N-terminal orientation) interacted with SURF4-HA from lysates of HEK293T cells overexpressing SURF4-HA. In contrast, GST alone recruited SURF4-HA poorly ( Figure 3A and Figure 3B To test whether the CW motif is important for the interaction between SURF4 and ShhN, we used cells encoding SURF4-Myc with either ShhN-HA or HA-tagged mouse ShhN with a CW motif deletion (ShhN Δ33-39 We performed co-immunoprecipitation (co-IP) experiments in HEK293T cells co-transfected with ShhN-HA plasmids. We found that the percentage of SURF4-Myc bound to ShhN-HA was significantly higher than that bound to mouse ShhN Δ33-39 -The percentage of SURF4-Myc in HA ( Figure 3C and Figure 3D ), indicating that ShhN interacts with SURF4 via the CW motif.
[0168] It is thought that, similar to its yeast homologue Erv29, the N- and C-termini of SURF4 are exposed on the cytoplasmic face of the ER (21, 31, 32). The structure of human SURF4 predicted by AlphaFold (33, 34) suggests that SURF4 consists of eight transmembrane helices ( Figure 3E). The cytoplasmic N-terminus of SURF4 is predicted to form an amphipathic helix with the hydrophobic side contacting the cytoplasmic leaflet of the lipid bilayer. Interestingly, the first luminal loop of SURF4 (aa: 49-60) is predicted to form a helix with three negatively charged residues pointing into the cavity ( Figure 3E Co-IP analysis showed that mutating these residues to alanine significantly reduced the interaction between SURF4-Myc and ShhN-HA ( Figure 3F to Figure 3G ).
[0169] To assay for direct interactions, we immobilized the first cavity loop of SURF4 (SEQRDYIDTTWNC; SEQ ID NO: 10, referred to as SURF4 cavity peptide) on beads and then used purified GST and Shh 25-49 -GST was used as prey for sedimentation assay ( Figure 3H ). Strikingly, we found that Shh 25-49 -GST interacts with the SURF4 luminal peptide, while GST does not interact with the SURF4 luminal peptide ( Fig. 3I As an additional test, we used a peptide corresponding to the CW motif (KRRHPKKC: SEQ ID NO: 6, referred to as CW peptide) as bait and used purified GST-SURF4 49-60 As prey for sedimentation analysis ( Figure 3J ). We found that GST-SURF4 49-60 Binds to CW peptide, while GST binds weakly ( Figure 3K ). The results of isothermal titration calorimetry (ITC) showed that GST-SURF4 49-60 With a K of 2.35 ± 0.09 μM d Binding to CW peptide, but no binding between GST and CW peptide was detected ( Figure 3L to Figure 3M ). Further analysis showed that GST-SURF4 49-60 The peptide bound more efficiently to the wild-type CW sequence ( Figure 3N , compare lanes 2 and 3; and Fig.3O Quantitative results in ( ). These results indicate that the CW motif directly interacts with the first luminal domain of SURF4 through electrostatic interactions. We then immobilized a peptide corresponding to the first intracellular loop of Frizzled6 (VRRFRYPERPC; SEQ ID NO: 11, referred to as RRFR peptide) (27) on the beads. Although the RRFR peptide is also positively charged, GST-SURF4 bound to the RRFR peptide 49-60The level of GST-SURF4 bound to CW peptide was significantly lower than that of GST-SURF4 bound to CW peptide. 49-60 Level ( Figure 3N , compare lanes 2 and 4; and Fig.3O Quantitative results in ).
[0170] SURF4 has been shown to localize to the ER, ERES, and ER-Golgi intermediate compartment (ERGIC) (20, 22). Mutations in the COPI binding motif of SURF4 or expression of the GTPase-deficient mutant form of Arf1, Arf1(Q71L), accumulated SURF4 in the Golgi, indicating that SURF4 cycles between the ER and the Golgi (21). When SURF4-HA was co-expressed with SBP-EGFP-ShhN, SURF4-HA localized to the ER in the absence of biotin in approximately 60% of cells co-expressing SURF4 and ShhN ( Fig.13A Picture AC and Fig. 13B Quantitative results in ). 20 minutes after biotin treatment, SBP-EGFP-ShhN was localized in the juxtanuclear Golgi region ( Fig.13A Interestingly, 20 min after biotin treatment, SURF4-HA and SBP-EGFP-ShhN co-localized in the juxtanuclear Golgi region in about 90% of cells co-expressing SURF4 and ShhN ( Fig.13A Image DF and Fig. 13B Quantitative results in ). Quantitative results showed that 20 minutes after biotin treatment, the proportion of cells showing near-nuclear SURF4-HA in co-expressing cells increased significantly ( Fig. 13B ). 60 min after biotin treatment, SBP-EGFP-ShhN was exported from the Golgi apparatus and localized to some intracellular punctate structures in the cytoplasm and near the cell surface ( Fig.13A Image G). In contrast, SURF4-HA was localized in the ER and Golgi regions at this time point ( Fig.13A Panel H). These analyses showed that SURF4 trafficked with SBP-EGFP-ShhN from the ER to the Golgi apparatus, where SURF4 was then recycled to the ER, while ShhN moved to the cell surface.
[0171] As an additional experiment to test whether SURF4 is transported to the Golgi apparatus together with ShhN, we compared the localization of SURF4 in HeLa cells 20 min after biotin treatment with the localization of the cis-Golgi marker GM130 or the localization of the ERGIC marker ERGIC53. GM130 showed a juxtanuclear localization pattern ( Fig. 13C Image K). ERGIC53 showed punctate localization in the cell periphery and juxtanuclear localization ( Fig. 13CFigure L). The punctate form of ERGIC53 is adjacent to ERES (35), and the juxtanuclear form of ERGIC53 partially colocalizes with GM130 ( Fig. 13C Image M). 20 minutes after biotin treatment, most of SURF4-HA was located in the juxtanuclear region ( Fig.13E Figures P and T). The juxtanuclear localized SURF4 overlaps more with GM130 than with ERGIC53 ( Fig.13E Figures R and V). We quantified the colocalization between ERGIC53 and GM130 in the GM130-labeled juxtanuclear region ( Fig.13D We also quantified the colocalization of SURF4-HA with GM130 or ERGIC53 in the juxtanuclear region labeled by SBP-EGFP-ShhN ( Fig.13F ). The Pearson correlation coefficient (Pearson R value) was calculated as an indicator of colocalization. The quantitative results showed that the colocalization between SURF4-HA and GM130 was significantly higher than that between SURF4-HA and ERGIC53 ( Fig.13F , R values were 0.714 and 0.496, respectively). These analyses indicated that SURF4 and ShhN were transported together to the cis-Golgi apparatus 20 min after biotin treatment.
[0172] We performed co-IP experiments using HEK293T cells co-transfected with plasmids encoding SURF4-Myc and Str-KDEL_SBP-EGFP-ShhN-HA with or without biotin treatment. In the absence of biotin, most of SURF4 and ShhN localized to the ER ( Fig.13A Figures AC), and strongly co-IP ( FIG. 13G to FIG. 13H Under biotin treatment conditions, combined with incubation at 20°C to block cargo export from the TGN, most ShhN and SURF4 showed a Golgi-localized form ( Fig.13A Figure DF) and co-IP decreased ( FIG. 13G to FIG. 13H Together, these data suggest that ShhN and SURF4 interact at the ER and dissociate from each other upon entry into the Golgi apparatus.
[0173] Example 5—Proteoglycans (PGs) regulate ShhN export from the TGN
[0174] PGs are important for TGN export of soluble cargo proteins, including the soluble enzyme lipoprotein lipase (LPL) (36). Therefore, we tested whether PGs regulate TGN export of ShhN. We treated cells with xyloside, which inhibits GAG attachment during PG maturation. Treatment with xyloside did not cause defects in ER-to-Golgi transport of SBP-EGFP-ShhN ( FIG. 14A to FIG. 14B ). We then used the RUSH assay to analyze the kinetics of TGN export of ShhN. HeLa cells expressing Str-KDEL and SBP-EGFP-ShhN were incubated at 20°C in the presence of biotin to accumulate the cargo in the TGN and then shifted to 32°C to release the cargo. After incubation at 20°C, SBP-EGFP-ShhN accumulated in the juxtanuclear Golgi region, and no punctate structures were detected in the cytoplasm ( Figure 4A Figures AF, and enlarged views in Figures A' and D'). After 45 min of incubation at 32°C, SBP-EGFP-ShhN showed punctate localization in most cells ( Figure 4A Figure GI, and enlarged view in Figure 4G'). We speculate that these punctate structures are transport vesicles rich in SBP-EGFP-ShhN derived from the TGN. After xyloside treatment, the average number of punctate structures containing SBP-EGFP-ShhN per expressing cell was significantly reduced at 45 min after incubation at 32°C ( Figure 4A Figure JL, enlarged view in Figure J', and Figure 4B Quantitative results in ).
[0175] Next, we performed live imaging analysis to observe the surface delivery of SBP-EGFP-ShhN. We found that after biotin treatment, SBP-EGFP-ShhN was delivered to the juxtanuclear Golgi region ( Fig.15A Figures AH). We observed SBP-EGFP-ShhN punctate structures in the cytoplasm during post-Golgi transport of SBP-EGFP-ShhN, and most of these punctate structures showed obvious migration to the cell surface ( Fig.15A Figures CD and GH, and enlarged views in Figures C'-D" and G'-H"). These punctate structures are post-Golgi vesicles. Compared with untreated cells, xyloside treatment did not block ER-to-Golgi transport of SBP-EGFP-ShhN ( Fig.15A Figures IJ and MN), but the number of punctate structures is greatly reduced during post-Golgi transport ( Fig.15A Figures KL and OP, and enlarged views in Figures K'-L" and O'-P", FIG. 15B to FIG. 15CIn drug-treated cells, we did not observe any obvious movement of the punctate structures toward the cell surface. The live imaging analysis is consistent with our analysis using fixed cells, thus indicating that PG synthesis regulates ShhN export from the TGN.
[0176] As an additional experiment to verify the effect of PG synthesis on the TGN export of ShhN, we knocked down the expression of xylosyltransferase 2 (XYLT2), which catalyzes the attachment of GAG chains to the PG core protein, using two different siRNAs ( Figure 4D We then performed a temperature shift experiment in which cells were incubated at 20°C in the presence of biotin to accumulate cargo in the TGN and then shifted to 32°C to release the cargo. We quantified the number of SBP-EGFP-ShhN puncta at 45 min after incubation at 32°C. The average number of SBP-EGFP-ShhN puncta per expressing cell was significantly reduced in cells transfected with either siRNA against XYLT2 ( Figure 4C Figure NS, enlarged views in Figures Q'-S', and Figure 4E ), indicating that the export of SBP-EGFP-ShhN from the TGN is defective in XYLT2 knockdown cells.
[0177] Example 6—PG competes with SURF4 for binding to ShhN and promotes ShhN transport through the Golgi
[0178] The CW motif of Shh interacts with the GAG chain of PG (37, 38). Mutation of this motif causes defects in hedgehog signaling in mice (37, 39). Using GST pulldown, we found that addition of the GAG heparin inhibited the interaction between ShhN and SURF4 in a concentration-dependent manner ( Figure 5A and Figure 5B ), indicating that heparin competes with SURF4 for binding to ShhN. Since GAG chains are attached to PG core proteins in the Golgi, we speculated that this competition would mediate the dissociation of SURF4 from ShhN at the Golgi. To verify this speculation, we performed cross-co-IP experiments in the absence (ER-localized complex) and presence (Golgi-localized complex) of biotin. Relative to co-precipitation under ER-localized conditions, precipitation of SURF4-Myc with the Golgi-localized ShhN RUSH construct was reduced ( Figure 5C In contrast, in XYLT2 knockdown cells, the abundance of SURF4 associated with the Golgi-localized SBP-EGFP-ShhN was equal to the abundance of SURF4 co-precipitated with the ER-localized cisterna ( Figure 5D ; Figure 5EQuantitative results in ). These analyses indicated that blocking PG synthesis caused a defect in the dissociation of SURF4 from ShhN at the Golgi apparatus.
[0179] After being delivered to the Golgi apparatus, the SURF4-ShhN complex dissociates through competitive interaction with PG. SURF4 is then recycled back to the ER via COPI vesicles, while ShhN associated with PG is exported to the cell surface ( Fig. 5F Figure F). This model predicts that a defect in SURF4 dissociation from ShhN at the Golgi apparatus could lead to two possible consequences: 1) SURF4 enters the TGN region in XYLT2 knockdown cells after biotin treatment; or 2) ShhN and its associated SURF4 accumulate at the cis-Golgi apparatus ( Fig. 5F Figure G). To test the first possibility, we analyzed the colocalization between endogenous SURF4 and TGN46 in XYLT2 KD cells 30 min after biotin treatment. However, we did not detect significant colocalization between SURF4 and TGN46 in control or knockdown cells ( Figure 5G (Image IP, enlarged views in images L' and P'). After the SURF4-ShhN complex is delivered to the Golgi, SURF4 is rapidly and continuously recycled back to the cis-Golgi, making it difficult to detect TGN-localized SURF4.
[0180] To test the second possibility, we analyzed the trafficking of SBP-EGFP-ShhN through the cis-Golgi in cells treated with biotin for 20 or 30 min. We quantified the colocalization between SBP-EGFP-ShhN and GM130 in the juxtanuclear region labeled by SBP-EGFP-ShhN. We found that the colocalization between GM130 and juxtanuclear localized SBP-EGFP-ShhN was significantly reduced in cells treated with biotin for 30 min compared with cells treated with biotin for 20 min ( Figure 5G Picture QV, enlarged view in pictures S' and V', Figure 5H ), thus demonstrating that SBP-EGFP-ShhN passes through the cis-Golgi during biotin treatment. In XYLY2 KD cells, we found that the colocalization between SBP-EGFP-ShhN and GM130 was significantly higher than that in control cells 30 min after biotin treatment ( Figure 5G TY, enlarged views in pictures V' and Y', Figure 5H Quantitative results in ). This analysis showed that blocking PG synthesis caused a defect in ShhN trafficking to the cis-Golgi.
[0181] Protein interaction and colocalization analyses provide evidence that PG displacement of SURF4 on ShhN is important for ShhN transport across the Golgi. In addition to this mechanism, many soluble cargo proteins dissociate from their receptors at low pH (40, 41). The pH of the ER lumen is nearly neutral, whereas the pH of the TGN lumen is approximately 6.0 (42). We found that lowering the pH from 7.2 to 6.0 did not cause a significant decrease in the abundance of SURF4-HA bound to Shh(25-49)-GST ( Fig.16A , compare lanes 1 and 3; Fig. 16B ), indicating that the weakly acidic pH at the TGN is unlikely to drive the release of SURF4 from ShhN. At pH 6.0, heparin still inhibited the ShhN-SURF4 interaction ( FIG. 16C to FIG. 16D ), indicating that PG can compete with SURF4 for ShhN binding in the weakly acidic environment of the TGN. However, we cannot rule out the possibility that other molecules also contribute to the release of SURF4 from ShhN at the Golgi, and that the released ShhN then binds to PG at the TGN for continued transport ( Figure 5G Panel H). The analysis here also suggests that the delay in intra-Golgi trafficking of ShhN in XYLT2 knockdown cells could indirectly interfere with TGN export.
[0182] Example 7—SURF4 and PG synthesis are important for ER and TGN export of full-length Shh, respectively
[0183] Given that the ShhN construct we used was not modified with cholesterol, we wanted to test the role of SURF4 under more native conditions. We therefore generated a RUSH construct of full-length Shh (SBP-EGFP-Shh FL To test whether the protein encoded by the RUSH construct could be converted into N-terminal and C-terminal fragments, Shh with an N-terminal or C-terminal HA tag was used. FL RUSH construct (SBP-EGFP-HA-Shh FL SBP-EGFP-Shh FL -HA) transfected HEK293T cells. Immunoblotting analysis showed that in the expression of SBP-EGFP-HA-Shh FL (HA-Shh FL In the cell lysate of HEK293T cells, two bands were detected by anti-HA antibody. Their molecular weights were similar to those of the predicted N-terminal fragment of Shh, SBP-EGFP-HA-ShhN (about 54 kDa) and the full-length precursor, SBP-EGFP-HA-Shh FL (about 80 kDa) Fig.17A , Lane 1). When SBP-EGFP-Shh was expressed FL -HA(Shh FL In the cell lysate of HEK293T cells containing HA (-HA), two major bands were detected by anti-HA antibody. The molecular weight was similar to that of the predicted C-terminal fragment of Shh, ShhC-HA (about 33 kDa) and the full-length precursor SBP-EGFP-Shh. FL -HA (about 80kDa) Fig.17A , Lane 2). These analyses showed that SBP-EGFP-Shh FL SBP-EGFP-Shh was not detected in the culture medium fractions from cells treated with biotin. FL ( Fig. 17B We believe that SBP-EGFP-HA-Shh FL The N-terminal fragment generated by cleavage is modified with cholesterol, and this modification prevents the N-terminal fragment from being released from the plasma membrane into the culture medium. We also detected the presence of converted Shh in cell lysates after biotin treatment. FL The abundance of RUSH fusions decreased (compare Fig. 17B We speculated that some N-terminal fragments of Shh were internalized and sent to lysosomes for degradation after being delivered to the cell surface. Therefore, we performed immunofluorescence to observe the conversion of Shh fragments in cells expressing SBP-EGFP-Shh. FL -HA localization in HeLa cells. The transformed N-terminal fragment of Shh was annotated as SBP-EGFP-ShhN, and the transformed C-terminal domain of Shh was annotated as ShhC-HA. In the absence of biotin, SBP-EGFP-ShhN and ShhC-HA localize to the ER ( Fig. 17C Figure CE). 20 min after biotin treatment, about 80% of the cells showed Golgi-localized SBP-EGFP-ShhN, while ShhC-HA remained in the ER ( Fig. 17C Picture FH and Fig.17D These results indicate that SBP-EGFP-Shh FL The N-terminal fragment can be transported from the ER to the Golgi apparatus, but the C-terminal fragment cannot.
[0184] Next, we use Shh FL RUSH constructs were used to analyze ER export and TGN export. We found that SBP-EGFP-Shh FL Can be delivered to the juxtanuclear Golgi region in a biotin-dependent manner ( Fig.18AFigure AF). In SURF4 knockdown cells, SBP-EGFP-Shh FL The kinetics of ER-to-Golgi transport of SURF4 was significantly reduced, and this defect was rescued by expressing siRNA-resistant SURF4-HA ( Fig.18A Image GR and Fig.18C Defects in ER-to-Golgi transport were also observed in SURF4 KO cells ( Fig.18B Image SX and Fig.18D ), and this defect was rescued by expressing siRNA-resistant SURF4-HA ( Fig.18B Image Y-AA and Fig.18D Quantitative results in ).
[0185] SBP-EGFP-Shh could not be unambiguously detected on the cell surface after biotin treatment FL , which may be because membrane-anchored proteins are rapidly internalized after delivery to the plasma membrane. To test whether PG synthesis is important for surface delivery of Shh, we used a RUSH construct containing an HA-tagged Shh (SBP-EGFP-HA-Shh FL ) and antibody uptake experiments were performed. Mouse anti-HA antibody was used to label SBP-EGFP-HA-Shh that had been delivered to the cell surface. FL , and SBP-EGFP-HA-Shh was labeled with rabbit anti-GFP antibody FL In the absence of biotin, Shh-expressing cells were not detected by mouse anti-HA antibody ( Fig. 6A Picture AC, Figure 6B ). One hour after biotin treatment, approximately 65% of cells expressing Shh were detected by anti-HA antibody in the absence of xyloside ( Fig. 6A Picture DF, Figure 6B In contrast, after biotin treatment, the percentage of cells expressing Shh detected by anti-HA antibody was significantly lower in the presence of xyloside (65% vs. 30%, Fig. 6A Picture GI, Figure 6B ). This result indicates that blocking PG synthesis will cause SBP-EGFP-HA-Shh FL After biotin treatment, many SBP-EGFP-HA-Shh cells treated with xyloside FL The juxtanuclear localization form and the ER-like form are shown ( Fig. 6A Image H). After biotin treatment, SBP-EGFP-HA-Shh FLThe continuous localization at the ER might be caused by the incomplete effectiveness of cycloheximide, or inappropriate Golgi-ER recycling of the SURF4-Shh complex in xyloside-treated cells.
[0186] To demonstrate that xyloside treatment does not cause a global secretion defect, we analyzed the trafficking of a RUSH construct of E-cadherin (SBP-EGFP-E-cadherin). After incubation at 20°C, SBP-EGFP-E-cadherin accumulated in the juxtanuclear Golgi region ( Fig.19A Pictures AC and Fig.19A Figure GI). After 45 min of incubation at 32°C, SBP-EGFP-E-cadherin was detectable on the cell surface or at cell junctions in most cells ( Fig.19A Picture DF, Fig.19B After incubation at 32°C, xyloside treatment did not cause defects in the surface delivery of SBP-EGFP-E-cadherin ( Fig.19A Photos JL and Fig.19B ), indicating that blocking PG synthesis does not block the TGN delivery of E-cadherin to the cell surface.
[0187] Finally, we performed a temperature shift experiment by incubating cells at 20°C for 2 h and then at 32°C for 45 min in the presence of biotin. We found that the average number of punctate structures containing SBP-EGFP-Shh per cell was significantly reduced after XYLT2 knockdown ( Figure 6C The enlarged views in pictures KP and N'-P', Fig.6D These analyses suggest that PG synthesis is essential for Shh FL The TGN export of the RUSH constructs is important.
[0188] Example 8—Shh Transport
[0189] Modulating the release of newly synthesized signaling molecules by regulating their secretion can affect downstream signaling pathways in target cells. Despite their fundamental importance, the underlying molecular mechanisms mediating the biosynthetic trafficking of signaling molecules remain largely unclear. We analyzed the trafficking of the secreted signaling molecule Shh. The sorting and secretion of newly synthesized Shh is achieved in several steps: Fig. 5F): 1) The cargo receptor SURF4 interacts with the CW motif of Shh, thereby packaging ShhN into COPII vesicles at the ER (step 1); 2) The SURF4-ShhN complex is delivered to the Golgi and dissociates (step 2); 3) The released SURF4 is recycled to the ER via COPI vesicles (step 3); 4) The released ShhN associates with PG and is exported from the TGN (step 4). We found that PG competes with SURF4 for binding to ShhN, and that defects in PG synthesis enhance the association of SURF4 with ShhN at the Golgi. These analyses suggest that PG is an important factor regulating the displacement of SURF4 from ShhN at the Golgi ( Fig. 5F Figure F). In addition to PG, other factors such as other charged molecules also contribute to the dissociation of SURF4 from ShhN at the Golgi ( Fig. 5F Picture H).
[0190] It has been shown that selective retention of proteins in the ER and the capture of cargo proteins in COPII vesicles can modulate the specificity of ER export (18). In addition to selective capture, cargo proteins can also leave the ER by bulk transport (18). In this mechanism, incorporation of cargo proteins into COPII vesicles occurs by default and is independent of receptors or export signals. Using the RUSH assay, we found that EGFP without the CW motif was not transported from the ER to the Golgi after 30 min of biotin treatment ( Fig.7D In contrast, the CW motif of Shh is sufficient to efficiently export EGFP from the ER ( Figure 1A to Figure 1B ). These analyses indicate that EGFP is not readily transported forward in large quantities via the bulk flux.
[0191] After being delivered to the target compartment, cargo proteins need to dissociate from their receptors, which are recycled back to the donor compartment for another round of cargo sorting. One mechanism that regulates this dissociation is the pH-sensitive ligand uncoupling mechanism (40, 41). This mechanism regulates the dissociation of soluble acid hydrolase precursors from their receptors, the mannose 6-phosphate receptor (M6PR), in endosomes so that the M6PR can be recycled to the TGN to mediate the next round of hydrolase transport (41). In this study, we revealed a direct electrostatic interaction between the CW motif and negatively charged residues located in the predicted first luminal loop of SURF4. We provide evidence that PG competes with SURF4 for interaction with the CW motif in Shh at the Golgi, providing a new pathway for the dissociation of cargo proteins from cargo receptors.
[0192] In addition to the transport of Shh, SURF4 also mediates the export of other soluble proteins from the ER, including lipoproteins, PCSK9, and extracellular dentin. SURF4 is also involved in ERES organization and interacts with the amino-terminal hydrophobic proline hydrophobic motif of soluble cargo proteins (19, 20, 22). The N-terminal tripeptide motif interacts with a domain on SURF4 that is distinct from the CW motif binding site on SURF4. Another possibility is that the N-terminal tripeptide motif interacts with SURF4 indirectly through an unknown cytokine. Since SURF4 contains a C-terminal recycling signal (21), SURF4 with a C-terminal HA tag may not have the same maximal capacity as SURF4 without the HA tag. In the RUSH assay, we found that SURF4-HA is transported from the ER to the Golgi along with ShhN and rescues the defect in ShhN transport from the ER to the Golgi. These analyses suggest that SURF4-HA functions to promote ER-to-Golgi transport of ShhN, although it may not have the same maximal capacity as the untagged SURF4 form. Knockout of Shh causes embryonic lethality and induces morphological defects in embryonic tissues, including the brain and eyes, spinal cord, axial skeleton, and limbs (43). Knockout of SURF4 also causes early embryonic lethality in mice, with all knockout embryos dying between embryonic days 3.5 and 9.5 (44). Our results suggest that Shh is a key SURF4 receptor and that knockout of SURF4 causes defects in Shh secretion, which results in defects in early embryonic development.
[0193] Proteoglycans consist of a core protein linked to sugars of the GAG family, including heparan sulfate, dermatan sulfate, keratin sulfate, and chondroitin sulfate (45). All of these proteoglycans have been shown to interact with a variety of signaling molecules (45). These interactions regulate the free diffusion of signaling molecules and enable proteoglycans to function as signal co-receptors to regulate signal transduction (46). In Drosophila, phosphatidylinositol proteoglycans of the heparan sulfate proteoglycan (HSPG) class located on the cell surface regulate the association of Hedgehog factors with lipoproteins to promote the release of Hedgehog factors in lipoprotein particles, thereby regulating the diffusion of Hedgehog factors through tissues (47). Heparan sulfate chains have been shown to regulate metalloproteinase-mediated release of Shh from producer cells (48) and Hedgehog signaling in target cells (47). The CW motif of Shh is important for interaction with heparan sulfate chains (37, 38). Mutation of this motif in Shh (R34A / K38A) in situ reduces the affinity between Shh and proteoglycans in the mouse cerebellum and reduces Shh-induced granule cell proliferation (37). Interestingly, the R34A / K38A mutation in Shh causes proliferation defects in neural progenitor cells but not tissue morphology defects (39). In this study, we reveal that the CW motif can be recognized by SURF4 and proteoglycans in sequence to mediate their surface delivery. In addition to ShhN, other secreted proteins containing the CW motif include bone morphogenetic protein (BMP) 8A, BMP8B, and extracellular sulfatase (Sulf)-1. We speculate that the SURF4-proteoglycan delivery mechanism may provide a universal regulation of ER-Golgi trafficking of proteins containing the CW motif.
[0194] PG regulates the TGN export of ShhN through two possible, non-mutually exclusive mechanisms: 1) Insufficient PG synthesis induces a delay in the intra-Golgi transport of ShhN, which indirectly interferes with subsequent TGN export; 2) PG functions as a cargo receptor that regulates the TGN sorting of Shh. The integral membrane proteoglycan syndecan-1 (SDC1) acts as a cargo receptor that regulates the TGN sorting of lipoprotein lipase (LPL) (36). SDC1 and LPL are co-secreted in sphingomyelin (SM)-rich secretory vesicles (36). Physical features of the SDC1 transmembrane domain drive association with the SM-rich membranes of the TGN, and this association concentrates SDC1 and associated LPL, thereby targeting SDC1 and bound LPL to the sphingomyelin secretory pathway (36).
[0195] The α-amino group of the N-terminal cysteine residue of Shh is modified by palmitoylation catalyzed by hedgehog acyltransferase (15, 49). Palmitoylation requires an N-terminal cysteine with a free amino group (15).FL In the RUSH constructs of ShhN or ShhN, the α-amino group of the N-terminal cysteine residue of Shh formed a peptide bond with the SBP-GFP tag, indicating that the ShhN or Shh used in our study FL The RUSH construct of ShhN was not palmitoylated. The RUSH construct of ShhN was efficiently secreted, indicating that palmitoylation is not required for the secretion of Shh.
[0196] In this study, we used mammalian cells exogenously expressing specific cargo proteins as a system to study the molecular mechanisms of cargo sorting. This system is amenable to biochemical and cell biological approaches to reveal new mechanistic insights. Ligand production by tumor cells or the surrounding stroma has been shown to activate the Hh signaling pathway and promote tumorigenesis (50-52). The protein interactions that mediate Shh sorting and secretion identified in our study provide new therapeutic targets to downregulate Hh signaling by inhibiting Shh secretion for cancer treatment.
[0197] sequence
[0198] SEQ ID NO:1:SURF4 sgRNA(AGTCGCGCTGCTCGCTCCAC)
[0199] SEQ ID NO: 2: siRNA against SURF4 (GCAGGAACTTCGTGCAGTA)
[0200] SEQ ID NO: 3: siRNA against SURF4 (GCATCCGTATGTGGTTCCA)
[0201] SEQ ID NO:4: siRNA against XYLT2 (CTGGTAGTGTGGAGCTTCA)
[0202] SEQ ID NO:5: siRNA against XYLT2 (GCGTGCACCTGTATTTCTA)
[0203] SEQ ID NO:6: Cardin-Weintraub peptide (KRRHPKKC)
[0204] SEQ ID NO:7: Cardin-Weintraub peptide (RRRHPKK)
[0205] SEQ ID NO:8: Cardin-Weintraub peptide (KRRHPKK)
[0206] SEQ ID NO:9: Cardin-Weintraub peptide MT Peptide (AAAHPAAC)
[0207] SEQ ID NO:10: SURF4 peptide (SEQRDYIDTTWNC)
[0208] SEQ ID NO: 11: RRFR peptide (VRRFRYPERPC)
[0209] SEQ ID NO:12: SURF4 peptide (SEQRDYIDTTWN)
[0210] SEQ ID NO: 13: Nucleotide sequence encoding the Cardin-Weintraub peptide of SEQ ID NO: 8 (AAGAGGAGGCACCCCAAAAAG)
[0211] SEQ ID NO: 14: Nucleotide sequence encoding the SURF4 peptide of SEQ ID NO: 10 (AGCGAGCAGCGCGACTACATCGACACCACCTGGAACTGC)
[0212] SEQ ID NO: 15: Human SURF4 amino acid sequence
[0213] (MGQNDLMGTAEDFADQFLRVTKQYLPHVARLCLISTFLED GIRMWFQWSEQRDYIDTTWNCGYLLASSFVFLNLLGQLTGCVLVLSRNFVQYACFGLFGIIALQTIAYSILWDLKFLMRNLALGGGLLLLLAESRSEGKSMFAGVPTMRESSPKQ YMQLGGRVLLVLMFMTLLHFDASFFSIVQNIVGTALMILVAIGFKTKLAALTLVVWLFAINVYFNAFWTIPVYKPMHDFLKYDFFQTMSVIGGLLLVVALGPGGVSMDEKKKEW)
[0214] SEQ ID NO: 16: Human SURF4 cDNA nucleotide sequence
[0215] (ATGGGCCAGAACGACCTGATGGGCACGGCCGAGGACTT CGCCGACCAGTTCCTCCGTGTCACAAAGCAGTACCTGCCCCACGTGGCGCGCCTCTGTCTGATCAGCACCTTCCTGGAGGACGGCATCCGTATGTGGTTCCAGTGGAGCGAGCAGCGCGACTACATCGACACCACCTGGAACTGCGGCTACCTGCTGGCCTCGTCCTTCGTCTTCCTCAACTTGCTGGGACAGCTGACTGGCTGCGTCCTGGTGTTGAGCAGGAACTTCGTGCAGTACGCCTGCTTCGGGCTCTTTGGAATCATAGCTCTGCAGACGATTGCCTACAGCATTTTATGGGACTTGAAGTTTTTGATGAGGAACCTGGCCCTGGGAGGAGGCCTGTTGCTGCTCCTAGCAGAATCCCGTTCTGAAGGGAAGAGCATGTTTGCGGGCGTCCCCACCATGCGTGAGAGCTCCCCCAAACAGTACATGCAGCTCGGAGGCAGGGTCTTGCTGGTTCTGATGTTCATGACCCTCCTTCACTTTGACGCCAGCTTCTTTTCTATTGTCCAGAACATCGTGGGCACAGCTCTGATGATTTTAGTGGCCATTGGTTTTAAAACCAAGCTGGCTGCTTTGACTCTTGTTGTGTGGCTCTTTGCCATCAACGTATATTTCAACGCCTTCTGGACCATTCCAGTCTACAAGCCCATGCATGACTTCCTGAAATACGACTTCTTCCAGACCATGTCGGTGATTGGGGGCTTGCTCCTGGTGGTGGCCCTGGGCCCTGGGGGTGTCTCCATGGATGAGAAGAAGAAGGAGTGGTAA)
[0216] SEQ ID NO:17: Amino acid sequence of human Sonic Hedgehog
[0217] (MLLLARCLLLVLVSSLLVCSGLACGPGRGFGKRRHPKKLT PLAYKQFIPNVAEKTLGASGRYEGKISRNSERFKELTPNYNPDIIFKDEENTGADRLMTQRCKDKLNALAISVMNQWPGVKLRVTEGWDEDGHHSEESLHYEGRAVDITTSDRDRSKYGMLARLAVEAGFDWVYYESKAHIHCSVKAENSVAAKSGGCFPGSATVHLEQGGTKLVKDLSPGDRVLAADDQGRLLYSDFLTFLDRDDGAKKVFYVIETREPRERLLLTAAHLLFVAPHNDSATGEPEASSGSGPPSGGALGPRALFASRVRPGQRVYVVAERDGDRRLLPAAVHSVTLSEEAAGAYAPLTAQGTILINRVLASCYAVIEEHSWAHRAFAPFRLAHALLAALAPARTDRGGD SGGGDRGGGGGRVALTAPGAADAPGAGATAGIHWYSQLLYQIGTWLLDSEALHPLGMAVKSS)
[0218] SEQ ID NO:18: Human Sonic Hedgehog cDNA nucleotide sequence
[0219]
[0220] It should be understood that the examples and embodiments described herein are for illustrative purposes only, and that those skilled in the art may conceive of various modifications or changes based on these examples and embodiments, and thus these modifications or changes will be included in the spirit and scope of the present application and the scope of the appended claims. In addition, any element or limitation of any invention or embodiment disclosed herein may be combined with any and / or all other elements or limitations disclosed herein (alone or in any combination) or any other invention or embodiment thereof, and all such combinations are included within the scope of the present invention, but are not limited thereto.
[0221] Exemplary embodiments
[0222] The present invention may be better understood by reference to certain illustrative examples, which include but are not limited to the following embodiments:
[0223] Embodiment 1. A polypeptide molecule selected from the group consisting of the following i) to iii):
[0224] i) a polypeptide molecule comprising SEQ ID NO: 6-8;
[0225] ii) a polypeptide molecule comprising SEQ ID NO: 10; or
[0226] iii) a polypeptide molecule having at least 90% sequence identity with the polypeptide of (i) or (ii).
[0227] Embodiment 2. An isolated polynucleotide encoding the polypeptide according to embodiment 1.
[0228] Embodiment 3. The polypeptide according to embodiment 1, wherein the polypeptide blocks the interaction between excess locus protein 4 (SURF4) and sonic hedgehog (Shh).
[0229] Embodiment 4. The polypeptide of embodiment 1, wherein the polypeptide binds to Shh.
[0230] Embodiment 5. A composition comprising the polypeptide according to embodiment 1.
[0231] Embodiment 6. The composition according to embodiment 5 further comprises a pharmaceutically acceptable carrier and / or excipient.
[0232] Embodiment 7. A method for inhibiting Hh signaling pathway, the method comprising administering to a subject a composition comprising a macromolecule that blocks the interaction between SURF4 and Shh or the polypeptide molecule according to embodiment 1.
[0233] Embodiment 8. The method according to embodiment 7, wherein the polypeptide molecule blocks the interaction between SURF4 and Shh.
[0234] Embodiment 9. The method according to embodiment 7, wherein the polypeptide molecule binds to Shh.
[0235] Embodiment 10. The method of embodiment 7, wherein the macromolecule is a glycosaminoglycan.
[0236] Embodiment 11. The method according to embodiment 10, wherein the glycosaminoglycan is heparin, heparin sulfate, heparin sulfate proteoglycan (HSPG), or chondroitin sulfate proteoglycan (CSPG).
[0237] Embodiment 12. The method of embodiment 7, wherein the subject suffers from a ligand-dependent cancer.
[0238] Embodiment 13. A method according to embodiment 7, wherein the subject is human.
[0239] Embodiment 14. The method according to embodiment 7, wherein the composition further comprises a pharmaceutically acceptable carrier and / or excipient.
[0240] Embodiment 15. A method for inhibiting the Hh signaling pathway, the method comprising mutating the following in a subject:
[0241] i) amino acid residues E50, D53, D56 of human SURF4 or any combination thereof;
[0242] ii) nucleotides encoding amino acid residues E50, D53, D56 of human SURF4 or any combination thereof;
[0243] iii) amino acid residues 32, 33, 34, 35, 36, 37, 38 of human Shh or any combination thereof; or
[0244] iv) nucleotides encoding amino acid residues 32, 33, 34, 35, 36, 37, 38 of human Shh or any combination thereof.
[0245] Embodiment 16. The method according to embodiment 15, wherein the mutation of i) to iv) inhibits the interaction of SURF4 with Shh in the subject.
[0246] Embodiment 17. The method of embodiment 15, wherein the subject suffers from a ligand-dependent cancer.
[0247] Embodiment 18. A method according to embodiment 15, wherein the subject is human.
[0248] References
[0249] 1. P. W. Ingham, Y. Nakano, C. Seger, Mechanisms and functions of Hedgehog signalling across the metazoa. Nat Rev Genet 12, 393 - 406 (2011).
[0251] 2. R. Petrova, A. L. Joyner, Roles for Hedgehog signaling in adult organ homeostasis and repair. Development 141, 3445 - 3457(2014). 3. J. L. Mullor, P. Sanchez, A. Ruiz i Altaba, Pathways and consequences: Hedgehog signaling in human disease. Trends Cell Biol 12, 562 - 569(2002).
[0252] 4. P. W. Ingham, M. Placzek, Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nat Rev Genet 7, 841 - 850(2006).
[0253] 5. B. St - Jacques, M. Hammerschmidt, A. P. McMahon, Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev 13,
[0254] 2072 - 2086(1999).
[0255] 6.M.J.Bitgood,L.Shen,A.P.McMahon,Sertoli cell signaling by Deserthedgehog regulates the male germline.Curr Biol 6,298-304 (1996).
[0257] 7.H.H.Yao,W.Whoriskey,B.Capel,Desert Hedgehog / Patched 1
[0258] signaling specifies fetal Leydig cell fate in testis organogenesis.
[0259] Genes Dev 16,1433-1440(2002).
[0260] 8.M.Wijgerde,M.Ooms,J.W.Hoogerbrugge,J.A.Grootegoed,Hedgehogsignaling in mouse ovary:Indian hedgehog and desert hedgehog from granulosacells induce target gene expression in developing theca cells.Endocrinology146,3558-3566(2005).
[0261] 9.E.Dessaud,A.P.McMahon,J.Briscoe,Pattern formation in the vertebrateneural tube:a sonic hedgehog morphogen-regulated transcriptionalnetwork.Development 135,2489-2503(2008).
[0262] 10.P.T.Yam,F.Charron,Signaling mechanisms of non-conventional axonguidance cues:the Shh,BMP and Wnt morphogens.Curr Opin Neurobiol 23,965-973(2013).
[0263] 11.A.P.McMahon,P.W.Ingham,C.J.Tabin,Developmental roles and clinicalsignificance of hedgehog signaling.Curr Top Dev Biol 53,
[0264] 1-114(2003).
[0265] 12.X.Chen et al.,Processing and turnover of the Hedgehog protein inthe endoplasmic reticulum.J Cell Biol 192,825-838(2011).
[0266] 13.I.A.Rose,J.V.Warms,An enzyme with ubiquitin carboxy-terminalesterase activity from reticulocytes.Biochemistry 22,4234-4237 (1983).
[0268] 14.J.A.Porter,K.E.Young,P.A.Beachy,Cholesterol modification ofhedgehog signaling proteins in animal development.Science 274,
[0269] 255-259(1996).
[0270] 15.J.A.Buglino,M.D.Resh,Hhat is a palmitoylacyltransferase withspecificity for N-palmitoylation of Sonic Hedgehog.J Biol Chem 283,
[0271] 22076-22088(2008).
[0272] 16.J.Dancourt,C.Barlowe,Protein sorting receptors in the earlysecretory pathway.Annu Rev Biochem 79,777-802(2010).
[0273] 17.A.Schweizer,J.A.Fransen,T.Bachi,L.Ginsel,H.P.Hauri,Identification,by a monoclonal antibody,of a 53-kD protein associated with a tubulo-vesicular compartment at the cis-side of the Golgi apparatus.J Cell Biol 107,1643-1653(1988).
[0274] 18.C.Barlowe,A.Helenius,Cargo Capture and Bulk Flow in the EarlySecretory Pathway.Annu Rev Cell Dev Biol 32,197-222(2016).
[0275] 19.K.Saegusa,M.Sato,N.Morooka,T.Hara,K.Sato,SFT-4 / Surf4
[0276] control ER export of soluble cargo proteins and participate in ERexit site organization.J Cell Biol 217,2073-2085(2018).
[0277] 20.B.T.Emmer et al.,The cargo receptor SURF4 promotes the efficientcellular secretion of PCSK9.Elife 7(2018).
[0278] 21.X.Wang et al.,Receptor-Mediated ER Export of Lipoproteins ControlsLipid Homeostasis in Mice and Humans.Cell Metab
[0279] 10.1016 / j.cmet.2020.10.020(2020).
[0280] 22.Y.Yin et al.,Surf4(Erv29p)binds amino-terminal tripeptide motifsof soluble cargo proteins with different affinities,enabling prioritizationof their exit from the endoplasmic reticulum.PLoS Biol
[0281] 16,e2005140(2018).
[0282] 23.G.Boncompain et al.,Synchronization of secretory protein trafficin populations of cells.Nat Methods 9,493-498(2012).
[0283] 24.A.D.Cardin,H.J.Weintraub,Molecular modeling of protein-glycosaminoglycan interactions.Arteriosclerosis 9,21-32 (1989).
[0285] 25.M.Aridor,S.I.Bannykh,T.Rowe,W.E.Balch,Sequential coupling betweenCOPII and COPI vesicle coats in endoplasmic reticulum to Golgi transport.JCell Biol 131,875-893(1995).
[0286] 26.L.Niu et al.,Atlastin-mediated membrane tethering is critical forcargo mobility and exit from the endoplasmic reticulum.Proc Natl Acad Sci U SA 116,14029-14038(2019).
[0287] 27.X.Tang et al.,Molecular mechanisms that regulate export of theplanar cell-polarity protein Frizzled-6 out of the endoplasmic reticulum.JBiol Chem 10.1074 / jbc.RA120.012835(2020).
[0288] 28.Y.Huang et al.,An in vitro vesicle formation assay reveals cargoclients and factors that mediate vesicular trafficking.Proc Natl Acad Sci U SA 118(2021).
[0289] 29.Y.Guo,A.D.Linstedt,COPII-Golgi protein interactions regulate COPIIcoat assembly and Golgi size.J Cell Biol 174,53-63(2006).30.F.Yang,T.Li,Z.Peng,Y.Liu,Y.Guo,The amphipathic helices of Arfrp1 and Arl14 are sufficientto determine subcellular localizations.
[0290] J Biol Chem 10.1074 / jbc.RA120.014999(2020).
[0291] 31.S.Otte,C.Barlowe,Sorting signals can direct receptor-mediatedexport of soluble proteins into COPII vesicles.Nat Cell Biol 6,
[0292] 1189-1194(2004).
[0293] 32.W.J.Belden,C.Barlowe,Role of Erv29p in collecting solublesecretory proteins into ER-derived transport vesicles.Science 294,
[0294] 1528-1531(2001).
[0295] 33.M.Varadi et al.,AlphaFold Protein Structure Database:massivelyexpanding the structural coverage of protein-sequence space with high-accuracy models.Nucleic Acids Res 10.1093 / nar / gkab1061 (2021).
[0297] 34.J.Jumper et al.,Highly accurate protein structure prediction withAlphaFold.Nature 596,583-589(2021).
[0298] 35.H.Hughes et al.,Organisation of human ER-exit sites:requirementsfor the localisation of Sec16 to transitional ER.J Cell Sci 122,
[0299] 2924-2934(2009).
[0300] 36.E.L.Sundberg,Y.Deng,C.G.Burd,Syndecan-1 Mediates Sorting ofSoluble Lipoprotein Lipase with Sphingomyelin-Rich Membrane in the GolgiApparatus.Dev Cell 51,387-398 e384(2019).
[0301] 37.J.B.Rubin,Y.Choi,R.A.Segal,Cerebellar proteoglycans regulate sonichedgehog responses during development.Development 129,
[0302] 2223-2232(2002).
[0303] 38.P.Farshi et al.,Dual roles of the Cardin-Weintraub motif inmultimeric Sonic hedgehog.J Biol Chem 286,23608-23619(2011).39.J.A.Chan etal.,Proteoglycan interactions with Sonic Hedgehog specify mitogenicresponses.Nat Neurosci 12,409-417(2009).
[0304] 40.C.G.Davis et al.,Acid-dependent ligand dissociation and recyclingof LDL receptor mediated by growth factor homology region.Nature
[0305] 326,760-765(1987).
[0306] 41.P.Ghosh,N.M.Dahms,S.Kornfeld,Mannose 6-phosphate receptors:
[0307] new twists in the tale.Nat Rev Mol Cell Biol 4,202-212(2003).
[0308] 42.P.Paroutis,N.Touret,S.Grinstein,The pH of the secretory pathway:
[0309] measurement,determinants,and regulation.Physiology(Bethesda)
[0310] 19,207-215(2004).
[0311] 43.C.Chiang et al.,Cyclopia and defective axial patterning in micelacking Sonic hedgehog gene function.Nature 383,407-413(1996).44.B.T.Emmer etal.,Murine Surf4 is essential for early embryonic development.PLoS One 15,e0227450(2020).
[0312] 45.T.Annaval et al.,Heparan Sulfate Proteoglycans Biosynthesis andPost Synthesis Mechanisms Combine Few Enzymes and Few Core Proteins toGenerate Extensive Structural and Functional Diversity.
[0313] Molecules 25(2020).
[0314] 46.P.Lu,V.M.Weaver,Z.Werb,The extracellular matrix:a dynamic niche incancer progression.J Cell Biol 196,395-406(2012).
[0315] 47.J.Briscoe,P.P.Therond,The mechanisms of Hedgehog signalling andits roles in development and disease.Nat Rev Mol Cell Biol 14,
[0316] 416-429(2013).
[0317] 48.T.Dierker,R.Dreier,A.Petersen,C.Bordych,K.Grobe,Heparan sulfate-modulated,metalloprotease-mediated sonic hedgehog release from producingcells.J Biol Chem 284,8013-8022(2009).
[0318] 49.R.B.Pepinsky et al.,Identification of a palmitic acid-modifiedform of human Sonic hedgehog.J Biol Chem 273,14037-14045(1998).50.D.M.Bermanet al.,Widespread requirement for Hedgehog ligand stimulation in growth ofdigestive tract tumours.Nature 425,
[0319] 846-851(2003).
[0320] 51.R.L.Yauch et al.,A paracrine requirement for hedgehog signallingin cancer.Nature 455,406-410(2008).
[0321] 52.M.Niyaz,M.S.Khan,S.Mudassar,Hedgehog Signaling:An Achilles'Heel inCancer.Transl Oncol 12,1334-1344(2019).
[0322] 53.R.Natarajan,A.D.Linstedt,A cycling cis-Golgi protein mediatesendosome-to-Golgi traffic.Mol Biol Cell 15,4798-4806(2004).
[0323] 54.Y.Guo,G.Zanetti,R.Schekman,A novel GTP-binding protein-adaptorprotein complex responsible for export of Vangl2
[0324] from the trans Golgi network.Elife 2,e00160(2013).
[0325] 55.X.Tang,F.Yang,Y.Guo,Cell-free Reconstitution of the Packaging ofCargo Proteins into Vesicles at the trans Golgi Network.Bio Protoc 10,e3537(2020).
[0326] 56.G.Boncompain et al.,Synchronization of secretory protein trafficin populations of cells.Nat Methods 9,493-498(2012).
[0327] 57.F.Yang,T.Li,Z.Peng,Y.Liu,Y.Guo,The amphipathic helices of Arfrp1and Arl14 are sufficient to determine subcellular localizations.
[0328] J Biol Chem 295,16643-16654(2020).
[0329] 58.Y.Guo,G.Zanetti,R.Schekman,A novel GTP-binding protein-adaptorprotein complex responsible for export of Vangl2
[0330] from the trans Golgi network.Elife 2,e00160(2013).
[0331] 59.X.Tang et al.,Molecular mechanisms that regulate export of theplanar cell-polarity protein Frizzled-6 out of the endoplasmic reticulum.JBiol Chem 10.1074 / jbc.RA120.012835(2020).
[0332] 60.X.Tang,F.Yang,Y.Guo,Cell-free Reconstitution of the Packaging ofCargo Proteins into Vesicles at the trans Golgi Network.Bio Protoc 10,e3537(2020).
Claims
1. A polypeptide molecule selected from the group consisting of: i) a polypeptide molecule comprising SEQ ID NO: 6-8; ii) a polypeptide molecule comprising SEQ ID NO: 10; and iii) a polypeptide molecule having at least 90% sequence identity with the polypeptide of (i) or (ii).
2. An isolated polynucleotide encoding the polypeptide according to claim 1.
3. The polypeptide according to claim 1, wherein the polypeptide blocks the interaction between excess locus protein 4 (SURF4) and sonic hedgehog (Shh).
4. The polypeptide of claim 1, wherein the polypeptide binds to Shh. A composition comprising the polypeptide according to claim 1. The composition according to claim 5 , further comprising a pharmaceutically acceptable carrier and / or excipient. 7 . A method for inhibiting Hh signaling pathway, comprising administering to a subject a composition comprising a macromolecule that blocks the interaction between SURF4 and Shh or the polypeptide molecule according to claim 1 . The method according to claim 7 , wherein the polypeptide molecule blocks the interaction between SURF4 and Shh.
9. The method of claim 7, wherein the polypeptide molecule binds to Shh.
10. The method of claim 7, wherein the macromolecule is a glycosaminoglycan.
11. The method of claim 10, wherein the glycosaminoglycan is heparin, heparin sulfate, heparin sulfate proteoglycan (HSPG), or chondroitin sulfate proteoglycan (CSPG).
12. The method of claim 7, wherein the subject suffers from a ligand-dependent cancer.
13. The method of claim 7, wherein the subject is a human.
14. The method of claim 7, wherein the composition further comprises a pharmaceutically acceptable carrier and / or excipient.
15. A method for inhibiting the Hh signaling pathway, the method comprising mutating the following substances in a subject: i) amino acid residues E50, D53, D56 of human SURF4 or any combination thereof; ii) nucleotides encoding amino acid residues E50, D53, D56 of human SURF4 or any combination thereof; iii) amino acid residues 32, 33, 34, 35, 36, 37, 38 of human Shh or any combination thereof; or iv) nucleotides encoding amino acid residues 32, 33, 34, 35, 36, 37, 38 of human Shh or any combination thereof.
16. The method of claim 15, wherein the mutations i) to iv) inhibit the interaction of SURF4 with Shh in the subject.
17. The method of claim 15, wherein the subject suffers from a ligand-dependent cancer.
18. The method of claim 15, wherein the subject is a human.
Citation Information
Patent Citations
Antibodies against sonic hedgehog homolog and uses thereof
CN102203135A
Compositions and methods for treating and diagnosing cancer
WO2005005601A2
Method and compositions to induce apoptosis of tumoral cells expressing shh
WO2011117328A1
Cancer-related biological materials in microvesicles
WO2012031008A2
